UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

Form 10-K

~~________________________~~________________________________________

(Mark one)
☒	Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934
For the fiscal year ended December 31, 2023
☐	Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934 For the transition period from ______________ to _____________

(Mark one)

~~________________________~~☒ Annual Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934

For the fiscal year ended December 31, 2024

☐ Transition Report Under Section 13 or 15(d) of The Securities Exchange Act of 1934

For the transition period from ______________ to _____________

________________________________________

Commission File Number: 000-54949

BioAdaptives, Inc.

(Exact name of registrant as specified in its charter)

Delaware		46-2592228
(State of incorporation)		(IRS Employer ID Number)

2620 Regatta Drive, Suite 102, Las Vegas, NV

(Address of principal executive offices)

(702) 659-8829

(Issuer’'s telephone number)

~~________________________~~________________________________________

Securities registered pursuant to Section 12 (b) of the Act - None

Securities registered pursuant to Section 12(g) of the Act: - Common Stock - $0.0001 par value

~~________________________~~________________________________________

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes ☐ No ☒

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes ☐ No ☒

Indicate by check mark whether the registrant has (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period the Company was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit and post files). Yes ☒ No ☐

Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not be contained, to the best of the registrant’s knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (Check one):

Large accelerated filer ☐ Accelerated filer ☐ Non-accelerated filer ☐☒ Smaller reporting company ☒

Indicate by check mark if the registrant has elected not to us the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(s) of the Exchange Act ☐

Indicate by check mark whether the registrant has filed a report on the attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b) ) by the registered public accounting firm that prepared or issued it audit report ☐

If securities are registered pursuant to section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to 240.10D-1(b) ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act): Yes ☐ No ☒

The aggregate market value of voting and non-voting common equity held by non-affiliates as of December 31, ~~2023~~2024 was approximately $~~358~~246,~~300.09~~461 based upon ~~895~~4,~~750~~107,~~225~~680 shares issued and outstanding.

As of December 31, ~~2023~~2024, there were ~~895~~4,~~750~~107,~~225~~680 shares of Common Stock issued and outstanding. As of March 2221, ~~2024~~2025, we had ~~972~~9,~~160~~048,~~641~~659 shares of our Common Stock issued and outstanding.

BioAdaptives, Inc.

Form 10-K for the Year Ended December 31, ~~2023~~2024

Index to Contents

Part I	BioAdaptives, Inc. Form 10-K for the Year Ended December 31, 2022 Index to Contents	Page Number
Item 1	Business	4
Item 1A	Risk Factors	6
Item 1B	Unresolved Staff Comments	11
Item 2	Properties	11
Item 3	Legal Proceedings	11
Item 4	Mine Safety Disclosures	11
Part II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and	12
Item 6	Selected Financial Data	13
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	13
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	16
Item 8	Financial Statements, Auditor’s Notes and Supplemental Data	16
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Controls and Procedures	39
Item 9B	Other Information	39
Part III
Item 10	Directors, Executive Officers and Corporate Governance	17
Item 11	Executive Compensation	21
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	21
Item 13	Certain Relationships and Related Transactions, and Director Independence	22
Item 14	Principal Accountant Fees and Services	23
Part IV
Item 15	Exhibits, Financial Statement Schedules	23
Item 16	Form 10-K Summary	23
Signatures		24

Part I		Page Number
Item 1	Business	4
Item 1A	Risk Factors	8
Item 1B	Unresolved Staff Comments	13
Item 2	Properties	13
Item 3	Legal Proceedings	13
Item 4	Mine Safety Disclosures	13
Part II
Item 5	Market for Registrant’s Common Equity, Related Stockholder Matters and	14
Item 6	Selected Financial Data	16
Item 7	Management’s Discussion and Analysis of Financial Condition and Results of Operations	16
Item 7A	Quantitative and Qualitative Disclosures About Market Risk	19
Item 8	Financial Statements, Auditor’s Notes and Supplemental Data	20
Item 9	Changes in and Disagreements with Accountants on Accounting and Financial Disclosure Controls and Procedures
Item 9B	Other Information
Part III
Item 10	Directors, Executive Officers and Corporate Governance	38
Item 11	Executive Compensation	41
Item 12	Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters	41
Item 13	Certain Relationships and Related Transactions, and Director Independence	42
Item 14	Principal Accountant Fees and Services	42
Part IV
Item 15	Exhibits, Financial Statement Schedules	43
Item 16	Form 10-K Summary	43
Signatures

Table of Contents

Caution Regarding Forward-Looking Information

Certain statements contained in this annual filing, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties, and other factors that may cause the actual results, performance, or achievements of the Company’s, or industry results, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements.

Such factors include, among others, the following: international, national and local general economic and market conditions: demographic changes; the ability of the Company to sustain, manage or forecast its growth; the ability of the Company to successfully make and integrate acquisitions; existing government regulations and changes in, or the failure to comply with, government regulations; adverse publicity; competition; fluctuations and difficulty in forecasting operating results; changes in business strategy or development plans; business disruptions; the ability to attract and retain qualified personnel; and other factors referenced in this and previous filings.

Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any ~~of the~~ forward-looking statements contained herein to reflect future events or developments.

Where You Can Find Information

The public may read and copy any materials we file with the SEC in the SEC’s Public Reference Section, Room 1580, at 100 F Street N.E., Washington, D.C. 20549. The public may obtain information on the operation of the Public Reference Section by calling the SEC at 1-800-SEC-0330. Additionally, the SEC maintains an Internet site that contains reports, proxy and information statements, and other information regarding issuers that file electronically with the SEC, which can be found at www.sec.gov or www.freeedgar.com.

Table of Contents

PART I

Item 1 - Business

The Company’s History

BioAdaptives, Inc., (“BioAdaptives,” the “Company,” “we” or “us”) was incorporated in the State of Delaware on April 19, 2013, as APEX 8 Inc. From inception through October 21, 2013, the Company was in the developmental stage and conducted virtually no business operations, other than organizational activities and preparation of a registration statement on Form 10-12g (the “Registration Statement”), which was filed with the U.S. Securities and Exchange Commission on May 3, 2013. On June 11, 2013, the SEC staff informed the Company that it had no further comments.

On January 10, 2014, the SEC notified the Company that the registration statement was effective. ~~and~~On on July 9, 2014, the Company’s shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.

On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public byusing ~~means of~~ the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the OTC market, and it also continued to execute its business plan.

On May 10, 2019, the Company filed a Form 10-12g with the SEC, re-entering the Continuous Disclosure program and registering its common stock under Section 12(g) of the Securities Exchange Act of 1934. On August 1, 2019, the SEC staff informed the Company that it had no further comments on this filing.

On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer.

On February 6, 2020, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series A Preferred Stock. ~~The~~ Series A has enhanced voting and conversion privileges and can be used by the Company to settle recorded debt or exchange for new product rights or techniques. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 100,000,000 to 200,000,000; holders of a majority of the Company’s common shares consented to the increase.

~~Effective~~On ~~May~~January 3126, ~~2021~~2022, Drthe Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. Series ~~Jacobs~~B ~~appointed~~has ~~Robert~~enhanced ~~Ellis~~voting and ~~Charles~~conversion ~~Townsend~~privileges asand ~~directors~~can ofbe used by the Company ~~and~~ to ~~serve~~acquire asownership ~~President~~of ~~and~~intellectual ~~Chief~~property ~~Operating~~rights ~~Officer~~and ~~respectively.~~other Drassets. On ~~Jacobs~~this ~~also~~same ~~appointed~~day, ~~Ronald~~the ~~Lambrecht~~Board asof Directors authorized an increase in the Company’s ~~Chief~~authorized ~~Financial~~common ~~Officer.~~stock ~~Effective~~from ~~December 31~~200,000,000 ~~2021~~to 750,000,000; ~~Mr.~~this ~~Lambrecht~~increase ~~resigned~~received the consent of the holders of a majority of the Company’s common shares.

On January 26, 2022, the Board of Directors exercised its authority under the Delaware General Corporations Law to establish its Series B Preferred Stock. The Series B has enhanced voting and conversion privileges and can be used by the Company to acquire ownership of intellectual property rights and other assets. On this same day, the Board of Directors authorized an increase in the Company’s authorized common stock from 200,000,000 to 750,000,000; this increase received the consent of the holders of a majority of the Company’s common shares.

Effective February 2, 2022, the Company acquired the exclusive option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen.

Table of Contents

On March 18, 2022, the Company filed a Form 1-A with the Securities and Exchange Commission covering a plan to sell up to 200,000,000 shares of common stock ~~for~~at prices between .005 and .01 per share. This was amended on October 7, 2022, to 250,000,000 shares of common stock at ~~the price of~~ 0.001.

~~June~~On 2February ~~2022.~~28, ~~BioAdaptives~~2023, ~~sponsored~~the aBoard ~~COVID~~of ~~Long~~Directors ~~Haul~~exercised ~~Survey~~its ~~conducted~~authority byunder ~~independent~~the ~~medical~~Delaware ~~researcher,~~General ~~Regina~~Corporation ~~Sutton,~~Law ~~M.D.,~~to ~~Gilbert,~~increase ~~Arizona.~~the ~~Dr.~~Company’s ~~Sutton,~~authorized ~~will~~common ~~study~~stock ~~the~~from ~~effects~~750,000,000 ofto ~~Bioadaptives’~~1,250,000,000; ~~nutraceuticals in~~ the ~~management~~holders of ~~chronic~~a ~~symptoms~~majority ~~associated~~of ~~with~~the ~~COVID~~Company’s –shares 19consented ~~infections~~to the increase.

On ~~February~~May 2815, ~~2023~~2024, ~~the~~Dr. ~~Board~~Edward ofJacobs ~~Directors~~retired ~~exercised~~from ~~its~~the ~~authority~~Company ~~under~~and ~~the~~was ~~Delaware~~succeeded ~~General~~by ~~Corporation~~Mr. ~~Law~~James toE. ~~increase~~Kneer ~~the~~as ~~Company’s~~Chairman ~~authorized~~and ~~common~~CEO. ~~stock~~As ~~from~~of ~~750~~May 27,~~000~~ 2024,~~000~~ toMr. ~~1,250,000,000;~~Gimhana ~~this~~Dissanayake ~~holders~~joined ofhim as a ~~majority~~Director of the Company~~’s shares consented to the increase~~.

On ~~September~~October 828, ~~2023~~2024, the ~~Company~~Board ~~registered~~unanimously ~~its~~resolved ~~Livestock~~to ~~Impact~~proceed ~~Division~~with as a ~~wholly~~reverse ~~owned~~split ~~subsidiary~~of in1 ~~Nevada~~for ~~with~~300 ~~200,000,000~~ shares ~~authorized and 10,000,000 preferred shares~~.

On ~~October~~November 1121, ~~2023~~2024, the ~~Company~~reverse ~~filed~~was ~~a Form 1-A with the Securities Exchange Commission covering a plan to sell up to 250,000,000 shares of common stock for prices between $0.001-0.003. This filing is ongoing.~~completed

On December 3, 2024, the Board approved a One-for-One Stock Dividend to holders of common stock.

The Company’s Business

Overview

BioAdaptives’ core business is toinvestigating, ~~investigate~~marketing, ~~market~~ and ~~distribute~~distributing natural plant, ~~algal~~fungi, and ~~mushroom~~algal-based products and medical devices that improve health and wellness for humans and animals,. ~~with~~The ancompany ~~emphasis~~emphasizes onweight ~~pain relief~~control, ~~anti-viral~~antiviral function, and anti-aging properties. BioAdaptives is reformulating its entire product line and will introduce new products in the first quarter of 2025.

~~Effective~~The ~~November~~Company’s ~~15,~~current ~~2021,~~products ~~the~~in ~~Company~~development ~~entered~~include ~~into~~ a ~~marketing~~weight ~~agreement~~management ~~for~~supplement anin ~~FDA-cleared~~a ~~medical~~Human ~~device~~Clinical trial, ~~the~~Zeranovia™. ~~Lung Flute~~Zeranovia™, ~~which~~is made of natural ingredients and uses proprietary methods of optimizing the ~~Company~~availability ~~called~~of ~~Lung~~nutrients ~~Cleanser™~~in foods and beverages. The ~~Company~~trials ishave ~~also~~shown ~~exploring~~better ~~agreements~~than expected results, with ~~other~~the ~~medical~~procedure ~~device~~positively ~~manufacturers;~~affecting ~~the~~participants, ~~owners~~with ofconsistent ~~intellectual~~weight ~~property~~loss ~~relating~~and minimal side effects. Zeranovia™ empowers users to ~~medical~~lose ~~devices~~weight ~~and~~while ~~processes;~~maintaining ~~and~~more ~~marketing~~lean ~~companies~~muscle ~~associated~~mass. ~~with~~Based ~~these~~on ~~manufacturers~~current ~~and~~results, ~~owners~~Zeranovia™ is expected to be introduced commercially in the second quarter of 2025.

~~The~~ Xcellara™ ~~Company’s~~regenerative ~~current~~stem ~~products~~cell ~~include~~activator ~~dietary~~is ~~supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients~~ in ~~foods~~production and ~~beverages.~~is ~~Human~~expected ~~products are designed~~ to ~~aid~~be ~~memory,~~sold ~~cognition~~commercially ~~and focus; assist~~ in ~~sleep~~April ~~and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness~~2025. ~~Our current product line for humans includes PluriPain®, PrimiLungs~~PawPa™~~,SleepEZ™,~~ ~~MindNMemory™~~Regen, ~~Cell~~the ~~Rejuven™~~canine ~~and~~treat ~~ProteinNMore™~~stem .cell Weactivator, ~~also~~will ~~market~~be ~~the~~available ~~Lung~~for ~~Flute™~~delivery ~~and PrimiLungs™ products~~ in ~~our~~April ~~Lung~~2025. ~~Armor~~PawPa™ ~~packaging,~~Regen ~~emphasizing~~supports ~~the~~ anti-~~viral~~aging ~~properties of the nutraceutical~~ and ~~general respiratory health benefits from use of the device~~wellness. ~~PluriPain®~~These isformulations aare ~~fast~~based ~~acting~~upon ~~long~~extensive ~~lasting~~trials ~~all~~on ~~natural pain relief formulation. MindnMemory™ is a nootropic formulation that enhances memory~~humans, ~~focus~~dogs, ~~mental clarity and endurance; PrimiSleep™ is a natural soporific that aids relaxation and sleep quality. Cell Rejuven™ increases energy and mobility and resistance to stress~~horses, ~~activates primitive cells~~hogs, ~~improves wound healing~~ and ~~promotes hair and nail growth~~mice. ~~ProteinNMore™~~The ~~aids~~canine inproducts ~~rapidly~~are ~~building~~all ~~lean bulk muscle, promotes muscle contractility and strength as well as helps~~ in ~~improving blood flow. We acquired~~ the ~~licenses~~form ~~for~~of ~~these products during 2021 and 2022~~treats, ~~and~~making ~~have~~delivery ~~commenced marketing activities for these products. Sales of the Lung Cleanser™ have not met our expectations~~ and wedosing ~~anticipate~~very ~~concentrating~~simple ~~in marketing this device through wholesale channels~~ and ~~on Amazon instead~~effective.

~~Our~~At ~~animal~~the ~~products~~request ~~include~~of ana ~~Equine~~member ~~All-in-One™~~of ~~and~~the ~~Equine~~BioAdaptives ~~All-In-One~~Board ~~Plus™~~of ~~formulation~~Advisors, ~~which~~BioAdaptives wedeveloped ~~market~~an toadvanced ~~trainers~~nootropic, ~~horse owners and boarding stables~~MyndMed™, ~~and~~it afocuses ~~Canine~~on ~~All-in-One™~~diverse ~~that~~pathways, wedelivering ~~market~~acetylcholine ~~directly~~(focus), todopamine ~~consumers.~~(mood), ~~Anecdotal~~GABA ~~and~~(calm), ~~testimonial~~antioxidants ~~reports are that the equine products provide significant relief from exercise induced pulmonary hemorrhaging~~(protection), asand ~~well~~energy as(mitochondria) ~~improved~~while ~~coat~~avoiding ~~and~~tolerance ~~mane appearance~~ and ~~hoof~~extending ~~health~~impact. ~~The~~MyndMed™ ~~canine~~is ~~products~~designed ~~have~~to ~~demonstrated~~improve ~~significant~~memory, ~~rejuvenating benefits for older dogs~~learning, ~~improving~~cognitive ~~overall appearance and energy levels. Effective April 2023~~enhancement, ~~FCBR~~mood Therapy Division has been appointed its exclusive Distributor for all LiveStock Impact’s products; the Company also negotiated with the supplier for the exclusive marketing rights to these products from the non-exclusive license it has held since June 2022. In this first quarter of the exclusive wholesale agreementsupport, ~~its wholesale volume has surpassed the past 9 months total by 400%. Granted due to the switch from retail to wholesale the margins are much tighter~~neuroprotection, ~~but we believe in 2024~~neuroplasticity, ~~the expanded sales will greatly benefit this wholly owned subsidiary~~ and ~~will~~stress ~~justify its eventual independence~~resilience.

~~The~~We ~~Company~~continue isresearching ~~also~~and ~~negotiating~~developing ~~distribution~~new ~~rights~~nutraceutical ~~to three additional human~~ products: ~~Pluripain~~for ~~PMS™,~~humans ~~which~~and isanimals ~~designed~~ to ~~help~~solve ~~manage~~problems ~~the~~and ~~symptoms~~deliver ~~associated with~~ the ~~menstrual cycle; VeganHepplus™, a liver support supplement; as well as NaturaComplete™, an All~~best-Inin-~~One~~class ~~dietary~~products. ~~supplement~~Our ~~formula~~products ~~with~~are ~~over 70 vitamins~~unique, ~~mineral~~well-designed, ~~amino~~ and ~~fatty~~proven ~~acids, trace minerals and other nutrients~~ to ~~support~~bring ~~general~~benefits, ~~health~~not ~~and~~just ~~obesity~~copying ~~management activities~~others. ~~These three new products are expected to be in market within first six months of 2024.~~

5 Table of Contents

Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Since June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product. However, since technical problems prevented completion of the planned pilot run, and no other suitable co-packer was identified, the Company is expected to not take up the option of purchasing this technology.

Since March 2023, the Company has been studying the FitYourOutfit® system, a low-cost AI smart phone app body composition tracking system to detect unwanted muscle mass loss reported with obesity management and also fat loss. In January 2024, BioAdaptives signed a Distributor’s agreement with PIXELCANDO SL to distribute this product in North America.

Since the latter part of March 2023, the Company has started to explore the Botanical Drugs sphere. We acquired the non-exclusive licenses from Dr. Yaguang Liu, LY Research for Glucose Management, Eye Health due to Myopia and Presbyopia and a resveratrol product. Dr Liu has had over 40 years of research and development in the Botanical Drugs area. We are exploring the opportunities in deploying these patented products for nutraceutical use for humans and animals. With Botanical drug interest being migrated to LiveStock Impact, Inc, the wholly owned subsidiary, Dr Liu has also migrated his directorship from BioAdaptives, Inc. to LiveStock Impact, Inc.

While BioAdaptives continue to investigate and acquire nutraceutical products for humans , all of our current activities are reliant on marketing and distributing products developed and owned by others. We do not own the formulations for our key products and manufacture and market them under an agreement with the developer that requires payment of a royalty and a license agreement. We are negotiating towards the acquisition of some of these formulations. Livestock Impact, Inc however, owns the exclusive marketing rights of the two equine formulations and one canine formulations.

We are reliant on direct web sales of the nutraceutical lines for human products and none of which has yet produced any significant revenue. In contrast, LiveStock Impact, Inc has been appointed an exclusive distributor and has increased its sales volume by 400%. Because of this, we are now exploring the wholesale and white label markets for the human supplement sales. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting.

Market and Marketing

WeBioAdaptives ~~market~~Inc. ~~our~~has ~~science-based,~~developed ~~quality~~a ~~nutraceuticals~~robust Direct to aConsumer ~~broad~~(DTC) ~~base~~digital ofmarketing ~~the~~campaign ~~population~~to inconnect ~~the~~directly Uwith its target audience.~~S.,~~ ~~and~~Leveraging ~~are~~platforms ~~exploring~~like ~~marketing~~social ~~prospects~~media, inemail ~~Asia~~marketing, ~~Australasia~~and a user-friendly website, the ~~Middle~~company ~~East,~~promotes ~~and~~its ~~Europe.~~supplement ~~The~~products ~~Company’s~~with ~~current~~engaging ~~target~~content ~~markets~~tailored ~~through~~to ~~LiveStock~~health-conscious ~~Impact,~~consumers. ~~Inc~~Through ~~also~~targeted ~~include~~ads, ~~equine~~informative blog posts, and ~~canine~~compelling ~~companion~~calls-to-action, ~~animals~~BioAdaptives ensures its messaging resonates, driving awareness and ~~equine~~conversions ~~competitors~~while infostering ~~the~~a ~~U.S.,~~community ~~Australasia~~around wellness and ~~the~~natural ~~Middle~~health ~~East~~solutions.

~~During~~In ~~June~~addition ~~2021, we commenced use of social media professionals and existing connections~~ to ~~create~~its ~~awareness~~DTC ~~about~~efforts, ~~our~~BioAdaptives ~~human~~has ~~products’~~forged ~~benefits.~~strategic ~~The~~partnerships ~~initial~~within ~~results~~the ~~were~~telehealth ~~not~~industry ~~satisfactory~~to ~~and~~enhance aits ~~recast, animal~~ product~~-specific~~ ~~program that followed later in 2021, did not achieve the desired results~~offerings. WeBy ~~are~~aligning ~~developing~~its ~~affiliate~~supplements ~~marketing~~as ~~opportunities~~both ~~and~~companion ~~recognize~~products ~~that a broader campaign using traditional advertising along with social media~~ and ~~more~~standalone ~~contemporary marketing tools is necessary. We started to re-launch our internet-based marketing activities in Q1 2023~~solutions, ~~extending~~the ~~individual~~company ~~product~~integrates ~~websites,~~seamlessly ~~revamping~~with ~~the~~telehealth ~~Company’s website~~platforms, ~~continuing~~providing toparticipants ~~explore~~with ~~wholesale~~accessible, ~~white~~science-~~label~~backed ~~opportunities~~options ~~and~~to ~~placing~~support ~~products~~their onwellness ~~Amazon~~journeys. ToThese ~~expand~~collaborations ~~its~~not ~~footprint~~only onexpand ~~the~~BioAdaptives’ ~~Amazon~~reach ~~sales~~but ~~channel,~~also weposition ~~are~~our ~~discussing~~products ~~with~~as ~~amazon~~trusted ~~marketing~~recommendations ~~specialists~~within ~~regarding~~virtual ~~third~~healthcare ~~party~~ecosystems, ~~management~~capitalizing ~~of our products~~ on ~~Amazon.~~the Sogrowing ~~far~~demand wefor ~~have~~telehealth ~~not been successful in expanding Amazon sales~~services.

We5 ~~are~~Table ~~pursuing scientific surveys and other testing to demonstrate the usefulness~~ of our products. While we do not anticipate developing testing protocols suitable for FDA approvals, we expect anecdotal and testimonial reports that will be useful in our marketing efforts. The Company participated in a survey involving the use of PluriPain® by patients suffering from Gadolinium Deposition Disease (“GDD”), and a combination of products for COVID Long Hauler patients. In the GDD survey, 60% of a small subject sample reported significant relief. The COVID Long Hauler survey has limited participation to date and no reported results. We continue to support these efforts.Contents

~~Although~~Finally, weBioAdaptives ~~believe~~employs ~~our~~a ~~last~~dynamic ~~formulated~~affiliate ~~MindNMemory™~~marketing ~~and~~program, ~~Cell~~partnering ~~Rejuven™~~with ~~products~~companies ~~are~~and ~~substantial~~individual ~~improvement~~influencers ~~over~~who ~~PrimiLive™~~boast ~~our~~large ~~other~~social ~~products~~media ~~have~~followings ~~not~~and ~~substantially~~proven ~~changed:~~success Wein ~~offer~~the ~~premium~~supplement ~~nutraceutical~~industry. ~~preparations~~These ~~containing~~affiliates, ~~the~~carefully ~~best~~selected ~~quality~~for ~~all-natural~~their ~~botanical,~~credibility ~~algal~~ and ~~mushroom~~performance, ~~ingredients.~~promote WeBioAdaptives’ ~~will~~products ~~continue~~through toauthentic ~~emphasize~~endorsements, ~~the~~affiliate ~~unique qualities~~links, ~~use~~ and ~~function~~promo ~~of our nutraceuticals~~codes. WeThis ~~intend~~strategy toamplifies ~~create~~brand ~~market share in our target demographic by (i) emphasizing the benefits of our proprietary algal-mushroom based~~visibility, ~~all-natural,~~drives ~~stimulant-free~~sales, ~~sugar-free, non-GMO ingredients that combine with proven Traditional Chinese Medicine~~ and ~~Ayurvedic~~builds ~~botanicals~~trust ~~into~~among ~~science-based~~niche ~~formulations~~audiences, ~~(ii)~~leveraging ~~investigating~~the ~~additional~~influence ~~products~~of inestablished ~~response~~voices toin ~~market~~the ~~demand~~health and ~~testing,~~wellness ~~and~~space ~~(iii) utilizing our marketing operation~~ to ~~act~~accelerate ~~as its sales and distribution arm to seek additional channels for sales coverage~~growth.

As noted above, we entered into licensing agreements for the PrimiLive™ and PrimiSleep™ products during 2021 and changed the name PrimiSleep™ to SleepEZ™ to reflect on its capabilities as well as developing our reformulated MindnMemory™ during 2022. We also launched the advanced Cell product, Cell Rejuven™. While these products are all-natural botanical formulations, as our other nutraceutical products, they represent a departure from our existing product lines because they are targeted to specific markets: MindnMemory™ is a nootropic, intended to improve concentration and mental acuity; with our initial marketing efforts oriented toward Seniors and e-gamers. SleepEZ™ is intended for use as an aid to relaxation, with an emphasis on improving the quality of sleep. Cell Rejuven™ is an improved primitive cell anti-aging formulation that promotes high quality hair and nail growth, as well as improving mood ProteinNMore™ is a unique turbo charged balanced premium protein blend We believe these products can be used in a complementary manner, to maintain on-task endurance and then to unwind and recover from such activities.

6 Table of Contents

We are furthering the use of a formulation of PluriPain® targeted toward the symptoms of pre-menstrual syndrome and menstrual pain. Anecdotal and testimonial reports have long noted that users obtain relief from these symptoms with use of the PluriPain® product, and we have made adjustments and additions to the formulation to target these symptoms. Early reports are promising, and we expect marketing efforts to emphasize the usefulness of our product to alleviate PMS-related symptoms. By popular requests, the Company is also working with developers on a menopause supplement and other targeted life style supplement aids.

We are also exploring the combination of PluriPain®, PrimiLung™ and SleepEZ™ for those still suffering COVID effects in the on-going Survey conducted by Regina Sutton, M.D. These specific formulations address some of the most troubling symptoms of long-term COVID sufferers, including brain fog, pain and sleep problems. We are encouraged that seniors who have been on Primilungs™ and Pluripain® as a combo has reported positive results this past cold season in assisting them with their breathing and comfort.

In light of the availability of marketing funding with the first Reg A completion, we collaborated with an agency and others to work on more far reaching press releases to promote our products, and to also conduct surveys with larger groups of participants to further confirm their efficacy, which anecdotal reports have in the past confirmed. We look forward to the new Reg A recently filed to be qualified to further the marketing effort in reaching seniors and specific communities, as well as spinning of LiveStock Impact, Inc as an independent associated Company of BioAdaptives.

With regard to animal products, the Company’s Livestock Impact wholly owned subsidiary under the guidance of its directors,Mr. Bruce Colclasure and Dr. Charles Timmerman D.V.M. Bruce Colclasure, a National Cutting Horse Association champion, who owns and operates the Flying C Bar Ranch in Oklahoma is a breeder and trainer of over 80 NCHA champion cutting horses. Dr. Charles Timmerman, D.V.M. established a veterinary an Aikens, SC clinic since 1973 helps to test new methods for the management of various animal health problems ,continues to explore new opportunities in this emerging market. Mr. Colclasure uses and endorses our Equine All-in-One™ and derivative booster products providing valuable feedback and testimonials regarding their benefits. Dr. Timmermann has been a central contributor of scientific and clinical guidance aimed at developing breakthrough animal health products. He has helped design and execute numerous animal tests and has provided critical oversight to identify product efficacy and ensure product safety. These efforts have resulted in a high-performance special formulation of our All-in-One product which continues to be marketed with exceptional results. We expect to expand the outreach in 2024 and also introduce new All-in-One products to enhance the exciting results.

In light of the failures of our past social media campaigns, we recommenced a social media effort in the third quarter with better response as well as continuing the annual sample giving programs this quarter. The Company continues its marketing affiliate outreach program for the human products, and will continue to directly contact the principals of senior communities, clubs and associations, offering discounts, samples and other inducements, seeking to develop “product champions” and “maven” relationships. We expect to contact principals in organizations with thousands of members and also to utilizetargeted advertising campaigns. With LiveStock Impact Inc, since the 4th Quarter 2022, we have been distributing samples and marketing materials to over 40 principals and influencers in regional and breed-specific equine associations and we are currently working with our exclusive distributor in a multi media advertising program for 2024.

With the new endeavor in the AI FitYourOutfit®(FYO) Body Composition tracking and reporting system, the Company is working at launching NaturaComplete™ All In One products. The ingredients in this product help to increase the bioavailable nutrients, providing more protein building blocks, stimulating the body’s primitive cells needed for immune defense, healing and promoting better quality skin, hair and nail. The concept that a single comprehensive blend of synergistic natural ingredients can provide safe and effective support for the immune system, and critical body organs including Brain, Heart, Lungs and Liver. This concept has been demonstrated in the highly popular and convenient one stop Equine All -In-One products that have shown to have rejuvenating, anti-aging and performance effects in horses. BioAdaptives encourages the use of NaturaComplete™ to be used with the AI supported FYO Body Composition System smart phone App so that one know if the sesired weight loss is due to a reduction of body fat as distinct from an unhealthy decrease in body water or lean muscle mass. The Company is looking to launch these products in the first two quarters of 2024.

The Company believes that the population growth in the seasoned and geriatric demographic cohort presents a unique opportunity. The World Health Organization has stated that the 60 years and over population segment will more than double from 11% to over 22% between 2000 and 2050, with the absolute number of people aged 60 and over expected to increase to 2 billion within the same period. The Company also recognizes the rising buying power and interests of the Millennials in wellness products and their choice of communication medium being social media and internet. It intends to establish a major focus to capture the anticipated growth in this sector. We believe that our social media promotion program will eventually gain traction and generate revenues. We are actively seeking a workable, efficient formula to grow consumer engagement and product sales.

The Company believes that international sales represent a significant future growth opportunity as aging population growth outside North America exceeds 1 billion people. The Company plans to aggressively pursue international sales by adding salespeople to its marketing effort, including use of social media, developing a network in high-growth APAC regions, and continuing its efforts to register products and trademarks in attractive foreign markets.

7 Table of Contents

Manufacturing

All of the Company’s nutraceutical products are considered dietary supplements or natural foods, and we carefully avoid making health, drug, or disease cure claims that could trigger regulatory compliance issues and affect our ability to market BioAdaptives ~~and LiveStock Impact~~ products. Our active ingredients are all plant-, ~~algal~~fungi, ~~and~~or ~~mushroom~~algal-based and sourced worldwide from reputable suppliers who employ stringent compliance and sustainable agriculture practices .

BioAdaptives actively investigates new products, techniques, and novel applications of existing products or technology in our research. The Company’s research ~~work~~ has ~~centered~~focused on ~~investigations~~investigating of all-natural supplement formulations that activate primitive cells, including stem cells and their derivatives, and natural ingredients that encourage stem cell proliferation. In 2022, the Company started a product line ~~of products~~ utilizing ~~both~~algae ~~Algae~~ and mushrooms.

With regard to medical devices, in April 2024, we ~~purchase~~purchased the ~~LungFlute~~Lungflute™ from athe ~~company~~sole ~~affiliated~~US ~~with~~affiliate of the patent holder. We do not expect to develop any direct capability to manufacture medical devices for numerous reasons, including a lack of capital and the fact that the amortized cost of such facilities, if we were to construct or acquire them, is generally far higher compared to the cost of ~~purchase~~purchasing of a finished product. We operate as a Research and Development nutraceutical company.

As noted above, it is our intention to operate primarily as a research and marketing company, developing consumer markets for nutraceutical products and medical devices that we license or market for others.

Employees

InAs ~~2023~~of May 2024, ~~The~~the Company has 3one full-time executive ~~employees and 3 part-time employees~~employee. We retain hourly labor ~~on an~~ as- needed ~~basis~~ and professional consultants to operate our business. The company’s management expects to use outside consultants, attorneys, and accountants as necessary. The need for additional employees and their availability will be addressed when deciding whether to acquire or participate in specific business opportunities.

The management of the Company expects to continue use of outside consultants, attorneys, and accountants, as necessary, so long as it is seeking and evaluating business opportunities.

The need for additional employees, and their availability, will be addressed in connection with the decision whether or not to acquire or participate in specific business opportunities.

Item 1A - Risk Factors

We have a limited operating history with our current business. The Company was incorporated in 2013 and was unsuccessful at previous business plans.

The Company has been engaged in the health and wellness industry since the FHI and BioSwan acquisitions in 2013. We have the benefit of their experience in developing and marketing nutraceutical products but understand that neither of them had significant success exploiting the products and technology we purchased. Future operations are subject to all the problems, expenses, difficulties, complications and delays encountered in establishing new businesses. The Company believes that it will become commercially viable, generate significant revenues, and operate at a profit in future periods but there are no assurances that we will meet these expectations.

The Company has no cash flows to support operations and relies on external sources to maintain the corporate entity.

Our revenues from product sales in the past have not been sufficient to cover our operating expenses, including the expenses associated with our status as a public company, or our research and marketing expenses. We have been reliant on outside financing sources, some of which are dependent on our status as a public company. All of these external sources are subject to general economic and market risks as well as regulatory factors that make future financing uncertain.

The Company will require additional financing to become commercially viable.

The Company’s continued existence is dependent on its ability to implement its business plan, generate sufficient cash flows from operations to support its daily operations, and provide sufficient resources to retire existing liabilities and obligations on a timely basis. ~~The~~Due ~~Company~~to ~~faces~~uncertainty ~~considerable~~in ~~risks~~our inability ~~its~~to ~~business~~raise ~~plan~~adequate ~~and~~capital ain ~~potential~~the ~~shortfall~~equity ofsecurities ~~funding~~market, ~~due~~the tocompany ~~uncertainty~~faces inconsiderable ~~our~~risks ~~ability~~in toits ~~raise~~business ~~adequate~~plan ~~capital~~and ina ~~the~~potential ~~equity~~shortfall ~~securities~~in ~~market~~funding.

~~During~~6 ~~the~~Table ~~period ended December 31, 2023, our revenues did not cover our expenses so that we were reliant on outside funding to continue operations. Our products are very good and for a variety~~ of reasons, including because we outsource our manufacturing, we are sufficiently nimble to increase production and sales if and when demand requires. However, our marketing and exposure suffers from lack of an advertising budget, which we have not yet been able to procure.Contents

During the period ended December 31, 2024, there is no sales revenue to cover our expenses so that we were reliant on investment funding to continue operations. Our new products are very good and for a variety of reasons, including because we outsource our manufacturing, we are sufficiently nimble to increase production and sales if and when demand requires. However, these products are still in the development stage and will not be on market till first or second quarter of 2025.

In the event that working capital sufficient to maintain the corporate entity and implement our business plan is not available, the Company’s existing stockholders have expressed their interest in the possibility of maintaining the corporate status of the Company and provide all necessary working capital on the Company’s behalf. However, no formal commitments or arrangements to advance or loan funds to the Company or repay any such advances or loans exist. There is no legal obligation for either management or existing controlling stockholders to provide additional future funding. Further, the Company is subject to future economic trends and the business operations for the Company’s existing controlling stockholders in order to have the resources available to support the Company.

8 Table of Contents

The Company anticipates offering future sales of equity securities. However, there is no assurance that the Company will be able to obtain additional funding through the sales of additional equity securities or, that such funding, if available, will be obtained on terms favorable to or affordable by the Company.

ToIn ~~date~~the past, a significant portion of our cash needs have been met through issuance of convertible debt securities. The notes generally carry Original Issue Discounts, provide for cash repayments during the first six (6) months after issuance (with a pre-payment penalty), and allow the holder to demand repayment by issuance of shares of common stock at a discount to market price. In function, these convertible notes act as private placements of our securities, with a variable subscription price based on market performance. On those terms, as subscription rather than debt, the rates and conversion amounts have so far been reasonable to us. Moreover, our agreements with these lenders contain representations that 1) there was no public solicitation for the notes, 2) that the note holders are “accredited” investors within the meaning of SEC Regulation D, and 3) that the holders will limit their conversions in a manner to assure they never hold more than 4.99% of the Company’s issued and outstanding shares. We have no assurances that we will be able to continue to borrow funds from these lenders and have been working to develop alternative financing means through more traditional methods.

~~Effective~~Since ~~March~~May 272024, ~~2023,~~ the Company’s ~~Articles~~has ofwelcome ~~Incorporation~~new ~~authorizes~~investment ~~the~~partners ~~issuance~~in ofacquiring upits topreferred ~~10,000,000~~D shares. ofShould ~~preferred~~future ~~stock~~needs ~~and 1~~arise,~~250,000,000~~ ~~shares~~the ~~of common stock. The~~ Company ~~has~~intends ~~established~~to araise ~~Series~~funds ~~A and Series B preferred stock with enhanced voting and conversion privileges for use~~ in ~~settling~~the ~~recorded~~equity ~~debt~~securities ~~and effecting acquisition of new products and technology~~market. The Company’s ~~ability~~believes tothat ~~issue~~its ~~preferred~~expectations ~~stock~~as ~~may~~to ~~limit~~its ~~the Company’s~~ ability to ~~obtain~~secure ~~debt~~additional orcapital ~~equity~~are ~~financing~~reasonable. asStill, ~~well~~there asis ~~impede~~no ~~the~~guarantee ~~implementation~~that of the Company’s ~~business~~will ~~plan.~~receive ~~The~~sufficient ~~Company’s~~funding ~~ability~~ to ~~issue~~sustain ~~these~~operations ~~authorized~~or ~~but~~implement ~~unissued~~any ~~securities~~future ~~may~~business ~~also~~plan ~~negatively impact our ability to raise additional capital through the sale of our debt or equity securities~~steps.

In such a restricted cash flow scenario, the Company would be unable to complete steps in its business plan and would, instead, delay all cash intensive activities. Without necessary cash flow, the Company may become dormant during the next twelve months, or until such time as necessary funds could be raised in the equity securities market. The Company believes that its expectations as to its ability to secure additional capital are reasonable but there is no guarantee that the Company will receive sufficient funding to sustain operations or implement any future business plan steps.

The Company filed a Form 1-A on March 4, 2022; this Reg A+ registration statement was declared effective. The Company raised up to $200,000 by the sale of up to 200,000,000 shares of common stock. It was fully subscribed in August 2023.

The Company filed a new Form 1-A on October 11, 2023 and this Reg A+ is ongoing in its filing. The Company is looking to raise up to $250,000 at a price range of $0.001 to 0.003. However, should the market conditions continues to be challenging, the pricing might be reviewed.

COVID-19 Pandemic Responses.

A novel strain of coronavirus (COVID-19) was first identified in December 2019, and subsequently declared a global pandemic by the World Health Organization on March 11, 2020. deadlines to postpone our quarterly filings during this period. In April 2020, the Company announced the launch of PrimiLungs™, an enhanced formulation of nutraceuticals promoting overall health and wellness through support of pulmonary immune systems. PrimiLungs™ is currently packaged with Lung Cleanser (aka Lung Flute) in an Immune Wellness Health Defense Package- Lung Armor™. We believe the business environment will continue to be conducive to products such as these during 2023 and beyond but can provide no assurances that our funding or other marketing initiatives will be any more successful.

The Company’s current business can be capital intensive.

The Company acknowledges that its Plan of Operations may not ~~result~~produce ina ~~the~~ consistent generation of positive working capital ~~in the near future~~shortly. We are in a consumer-driven market space that requires our development and marketing of attractive products, which is expensive. Although management believes ~~that~~ it will be able to successfully execute its business plan, which includes third -party financing and ~~the~~ raising of capital to meet the Company’s future liquidity needs, there can be no assurances. We anticipate continuous expenditures, some of which may be significant, to conduct research and development activities relating to existing and new products and marketing. These matters raise substantial doubt about the Company’s ability to continue as a going concern.

We currently rely on certain key individuals, and the loss of one of ~~these~~them ~~key individuals~~ could ~~have~~adversely anaffect ~~adverse effect on~~ the Company.

Our success depends to a certain degree upon certain key members of our management. These individuals are a significant factor in our growth and success. The loss of the services of such members of management could have a material adverse effect on our Company. We presently maintain no key-man insurance coverage on any of our officers.

The Company’s success will bedepend ~~dependent~~ in part ~~upon~~on its ability to attract qualified personnel and consultants.

The Company’s success will bedepend ~~dependent~~ in part upon its ability to attract qualified creative marketing, sales, and development professionals. The inability to do so on favorable terms may harm the Company’s proposed business.

9 Table of Contents

The Company must effectively meet the challenges of managing expanding operations.

The Company’s business plan anticipates that operations will ~~undergo~~significantly ~~significant~~expand ~~expansion~~ during ~~2023~~2025 and beyond. This expansion will require the Company to manage a larger and more complex organization, which could ~~place~~significantly ~~a significant~~ strain on our managerial, operational, and financial resources. Management may not succeed with these efforts. Failure to expand inefficiently ~~an efficient manner~~ could cause expenses to be greater than anticipated, revenues to grow more slowly than expected, and could otherwise have an adverse effect on the business, financial condition, and results of operations.

Table of Contents

Our business could be affected by changes in governmental regulation.

Federal, State, and Local laws and regulations governing food products and nutritional supplements are broad in scope and are subject to evolving interpretations, which could require us to incur substantial costs associated with compliance. In addition, violations of these laws, actual or alleged, could disrupt the Company’s planned business and adversely affect our financial condition and results of operations. In addition, ~~it is possible that~~ additional or revised Federal, State, and Local laws and regulations may be enacted in the future governing ~~thenutraceutical~~the mining industry. There can be no assurance that the Company will be able to comply with any such laws and regulations. ~~and~~Failure ~~its failure~~ to do so could significantly harm our business, financial condition, and results of operations.

Our business will be subject to other, uninsured operating risks, which may adversely affect the Company’s financial condition.

Our planned operations will be subject to risks ~~normally~~ordinarily incidental to our business activities. ~~and~~They will bedepend ~~dependent~~ on internal and third-party production and distribution operations that could result in work stoppages, ~~damage to~~ property damage, or unavailable ~~product~~products for resale. This may be caused by:

Breakdown of equipment.

Labor disputes.

Imposition of new government regulations.

Supply chain failures.

Product contamination.

Unanticipated ~~allergic~~allergy or other reactions.

Sabotage by operational personnel.

Cost overruns; and

Fire, flood, or other acts of God.

We market products that ~~are ingested by~~ our customers ingest and run additional risks incumbent toon the sales of ~~this~~these ~~manner of~~ consumer ~~good~~goods. Our existing insurance coverage would almost certainly be inadequate to deal with any ~~manner of~~ mass tort claim, and the ability of our suppliers to indemnify us is uncertain. Additionally, our contract suppliers ~~are~~rely ~~reliant~~ on source materials ~~that are~~ imported from China and other countries. Hence, ~~so that~~ we are subject to risks associated with interruptions or pricing increases due to political and other reasons.

We will likely face significant competition.

The nutraceutical industry is highly competitive, with numerous companies offering products that claim similar properties to ours. Some of these competitors are better capitalized, with the financial ability to effectively manage product development and marketing at levels we have not yet attained. While we believe our whole plant-, fungi, and algal-~~mushroom~~ based products have unique benefits that should lead to commercial success, BioAdaptive’s ability to effectively compete could be hindered by a lack of funds, poor positioning, management error, and other factors. The inability to effectively compete could adversely affect our business, financial condition, and results of operations.

RISKS RELATED TO OUR PUBLIC COMPANY STATUS AND OUR COMMON STOCK

Our internal controls may be inadequate, which could ~~cause~~make our financial reporting ~~to be~~ unreliable and lead to ~~misinformation~~the ~~being~~dissemination ~~disseminated~~of misinformation to the public.

Our management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Exchange Act Rule 13a-15(f), internal control over financial reporting is a process designed by, or under the supervision of, the principal executive and principal financial officer and effected by the board of directors, management and other personnel to provide reasonable assurances regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company; provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; and

~~pertain~~provide toreasonable assurance regarding the ~~maintenance~~prevention ofor ~~records~~timely ~~that~~detection inof ~~reasonable~~unauthorized ~~detail~~acquisition, ~~accurately~~use, ~~and~~or ~~fairly~~disposition ~~reflect~~of the ~~transactions~~Company’s ~~and~~assets ~~dispositions~~that ofcould ~~the~~have ~~assets~~a ofmaterial effect on the ~~Company;~~financial statements.

~~provide~~8 ~~reasonable~~Table ~~assurance that transactions are recorded as necessary to permit preparation~~ of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and/or directors of the Company; andContents

~~provide~~We ~~reasonable~~do ~~assurance~~not ~~regarding~~have ~~prevention~~a sufficient number of employees to segregate responsibilities. We may be unable to increase our staff or ~~timely~~engage ~~detection~~outside consultants or professionals to overcome our lack of ~~unauthorized~~employees. ~~acquisition~~During our testing, ~~use~~we ormay ~~disposition~~identify ofother deficiencies that we may not be able to remediate promptly. In addition, if we fail to achieve and maintain the ~~Company’s~~adequacy ~~assets~~of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that ~~could~~we can conclude on an ongoing basis that we have aadequate ~~material~~internal ~~effect~~controls onover financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes Oxley”). Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial ~~statements~~reports and are essential to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading

10 Table of Contents

We do not have a sufficient number of employees to segregate responsibilities and may be unable to afford increasing our staff or engaging outside consultants or professionals to overcome our lack of employees. During the course of our testing, we may identify other deficiencies that we may not be able to timely remediate. In addition, if we fail to achieve and maintain the adequacy of our internal controls, as such standards are modified, supplemented or amended from time to time, we may not be able to ensure that we can conclude on an ongoing basis that we have effective internal controls over financial reporting in accordance with Section 404 of the Sarbanes-Oxley Act of 2002 (“Sarbanes Oxley”). Moreover, effective internal controls, particularly those related to revenue recognition, are necessary for us to produce reliable financial reports and are important to help prevent financial fraud. If we cannot provide reliable financial reports or prevent fraud, our business and operating results could be harmed, investors could lose confidence in our reported financial information, and the trading price of our common stock, if a market ever develops, could drop significantly.

The costs of being a public company could result in us being unable to continue as a going concern.

As a public company, we ~~are~~must ~~required to~~ comply with numerous financial reporting and legal requirements, including those pertaining to audits and internal control. The costs of this compliance could be significant. If our revenues do not increase and/or we cannot satisfy many of these costs through the issuance of our shares, we may be unable to satisfy these costs in the normal course of business, ~~that~~resulting ~~would result~~ in our ~~being~~inability ~~unable~~ to continue as a going concern.

Management and the Board of Directors may be ~~Indemnified~~indemnified.

The Articles of Incorporation and Bylaws of BioAdaptives provide for the indemnification of directors and officers at the expense of the respective corporation and limit their liability. This may result in a ~~major~~significant cost to the corporation and hurt the interests of stockholders because corporate resources may be expended for the benefit of directors and officers. The Company has been advised that, in the opinion of the SEC, indemnification for liabilities arising under Federal Securities Laws is against public policy as expressed in the Securities Act and is, therefore, unenforceable.

The market for the BioAdaptives Shares is ~~extremely~~minimal ~~limited~~ and sporadic.

BioAdaptives’ common stock is quoted on the OTC Pink Sheets; trading is limited and sporadic. Trading in stock quoted on the Pink Sheets is often thin and characterized by wide fluctuations in trading prices, due to many factors that may have little to do with our operations or business prospects. This volatility could depress or exaggerate the market price of BioAdaptives’ common stock for reasons unrelated to operating performance. Moreover, the trading of securities in the Pink Sheets is often more sporadic than the trading of securities listed on a quotation system like NASDAQ, or a stock exchange like the New York Stock Exchange. These factors may impact on our ability to obtain financing in the future and will ~~certainly~~undoubtedly ~~have an~~ impact on the value of our common stock for shareholders.

BioAdaptives’ common stock is a penny stock, which is restricted by the SEC’s penny stock regulations and FINRA’s sales practice requirements,. ~~which~~These restrictions may limit a stockholder’s ability to buy and sell our common stock.

BioAdaptives’ common stock is a penny stock. The SEC has adopted Rule 15g-9, which generally defines “penny stock” toas be any equity security ~~that~~with ~~has~~ a market price (as defined) less than $5.00 per share or an exercise price of less than $5.00 per share, subject to certain exceptions. ~~Our~~These ~~common~~rules ~~stock~~cover isour ~~covered~~common ~~by these rules~~stock, which impose additional sales practice requirements on broker-dealers who sell to ~~persons~~people other than established customers and accredited investors. The term “accredited investor” refers generally to institutions with assets in excess of $5,000,000 or individuals with a net worth in excess of $1,000,000 or annual income exceeding $200,000 or $300,000 jointly with their spouse. The penny stock rules require a broker-dealer, prior to a transaction in a penny stock not otherwise exempt from the rules, to deliver a standardized risk disclosure document in a form prepared by the SEC which provides information about penny stocks and the nature and level of risks in the penny stock market. The broker-dealer also must provide the customer with current bid and offer quotations for the penny stock, the compensation of the broker-dealer and its salesperson in the transaction and monthly account statements showing the market value of each penny stock held in the customer’s account. The bid and offer quotations, and the broker-dealer and salesperson compensation information must be given to the customer orally or in writing prior to effecting the transaction and must be given to the customer in writing before or with the customer’s confirmation. In addition, the penny stock rules require that prior to a transaction in a penny stock not otherwise exempt from these rules the broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive the purchaser’s written agreement to the transaction. These disclosure requirements may have the effect of reducing the level of trading activity in the secondary market for the stock that is subject to these penny stock rules. Consequently, these penny stock rules may affect the ability of broker-dealers to trade our securities. We believe that the penny stock rules discourage investor interest in, and limit the marketability of, BioAdaptives’ common stock.

In addition to the penny stock rules promulgated by the SEC, FINRA (the Financial Industry Regulatory Authority) has adopted rules that require when recommending an investment to a customer a broker- dealer must have reasonable grounds for believing that the investment is suitable for that customer. ~~Prior~~Before to recommending speculative low -priced securities to their non-institutional customers, broker-dealers must make reasonable efforts to obtain information about the customer’s financial status, tax status, investment objectives, and other information. Under interpretations of these rules, ~~the~~ FINRA believes that there is a high probability that speculative low-priced securities will not be suitable for at least some customers. FINRA’s requirements make it more difficult for broker-dealers to recommend that their customers buy BioAdaptives’ common stock, which may limit ~~investor~~investors’ ability to buy and sell our common stock.

119 Table of Contents

The market for penny stocks has experienced numerous frauds and abuses that could adversely impact BioAdaptives’ common stock.

Company management believes that the market for penny stocks has suffered from patterns of fraud and abuse. Such patterns include:

control of the market for the security by one or a few broker-dealers that are often related to a promoter or issuer.

~~manipulation~~Manipulation of prices through prearranged matching of purchases and sales and false and misleading press releases.

~~boiler~~Boiler room practices involving high -pressure sales tactics and unrealistic price projections by salespersons.

~~excessive~~Excessive and undisclosed bid-ask differentials and markups by selling broker-dealers; and

wholesale dumping of the same securities by promoters and broker-dealers after prices have been manipulated to a desired level, along with the inevitable collapse of those prices with consequent investor losses.

BioAdaptives’ Board of Directors has the authority, without stockholder approval, to issue preferred stock with terms that may not be beneficial to common stockholders and with the ability to adversely affect common stockholder voting power and rights upon liquidation.

Our Certificate of Incorporation allows us to issue shares of preferred stock without any vote or further action by our stockholders. Our Board of Directors has the authority to fix and determine ~~the~~preferred stock’s relative rights and preferences ~~of preferred stock~~. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to holders of preferred stock the rights to our assets upon liquidation, the right to receive dividend payments before dividends are distributed to the holders of common stock and the right to the redemption of the shares, together with a premium, ~~prior~~before to the redemption of our common stock. We have ~~done so~~ recently, byestablished ~~establishing~~ the Series A Preferred Stock. We established the Series A Preferred Stock in 2020 and, ~~have~~subsequently, ~~recently established~~ the Series B and C Preferred Stock; these preferred shares provide holders with enhanced voting and conversion privileges ~~to holders~~. These privileges may impact the rights and privileges of common stockholders in certain circumstances. A Preferred Series D Stock was also approved by the Board in 2024.

Breath of Life’s and Preferred Share holders provision of a proxy to our Board of Directors permits us significant control over our business and may limit or eliminate minority stockholders’ ability to influence corporate affairs.

As a result of the Preferred shareholders and Breath of Life provisions of voting privileges to our Board of Directors, our directors not only control BioAdaptives’ business affairs, management and governance but also determine their own election and appointment. This arrangement places an extraordinary burden on the directors to adhere to their fiduciary responsibilities and practically limits the ability of minority shareholders to impact their decisions except through dissent or derivative litigation that may be expensive, impractical or both. The interests of our directors may differ from the interests of other stockholders with respect to the issuance of shares, business transactions with or sales to other companies, selection of other officers and directors and other business decisions. The minority stockholders have no way of overriding decisions made by our directors except through persuasion and litigation. This level of control may also have an adverse impact on the market value of our shares because our principal stockholders may institute or undertake transactions, policies or programs that result in losses and/or may not take any steps to increase our visibility in the financial community and/or may sell sufficient numbers of shares to significantly decrease our price per share.

We do not expect to pay cash dividends in the foreseeable future.

The Company has never paid cash dividends on its common stock and does not expect to pay a cash dividend on its common stock at any time in the foreseeable future. The future payment of dividends depends upon future earnings, capital requirements, financial requirements and other factors that the Company’s board of directors will consider. Since we do not anticipate paying cash dividends on the common stock, return on investment, if any, will depend solely on an increase, if any, in the market value of the common stock.

Future sales of shares of BioAdaptives common stock pursuant to Reg. A+ and Rule 144 under the Securities Act could adversely affect the market price of BIOADAPTIVES’s common stock.

As of March 2224, ~~2024~~2025, the Company has ~~972~~9,~~160~~048,~~641~~659 outstanding shares of its common stock, all of which were issued pursuant to registration statements and/or exemptions from registration under the Securities Act and applicable State Securities Laws. As of the date of this filing, ~~953~~4,~~807~~046,~~169~~659 are on deposit with CEDE & Co. and are publicly trading or tradeable, and nearly all of the balance is held by purchasers or service providers who obtained shares more than one year ago. All of these “aged” issued and outstanding shares are ~~all~~ now available for public sale ~~pursuant~~under to Rule 144 under the Securities Act and comparable exemptions under applicable state securities laws. The potential of such sales could adversely affect the market price of BioAdaptives’ common stock. The impact of these sales on the market cannot be reasonably estimated but absent significant positive news regarding our activities shareholders should expect an adverse impact on market price.

Conversions of Series A or -B-C-D Preferred Stock to common stock and resales could adversely affect the market price of BIOADAPTIVES’ common stock. Preferred stock ownership provides additional voting rights that may affect management.

~~The~~As ~~Company~~of ~~has~~the ~~3,350,000~~date ~~shares~~ of ~~its~~this ~~Series~~filing, Athe ~~Preferred~~company ~~Stock~~had ~~issued and outstanding and 2~~1,~~750~~093,~~000~~521 shares of its Series A, B, ~~Preferred~~C, ~~Stock~~and asD ofPreferred ~~the~~Stock ~~date~~issued ofand ~~this filing~~outstanding. These shares have enhanced voting and conversion privileges, so ~~that~~ the owners can either convert to common shares, which could impact market price, or hold and vote the shares under the circumstances set out in the Certificate of Designation, allowing them an increased authority over certain corporate functions.

12Because ~~Table~~we are not subject to compliance with rules requiring the adoption of ~~Contents~~certain corporate governance measures, our stockholders have limited protection against interested-director transactions, conflicts of interest, and similar matters.

~~Because~~The weSarbanes-Oxley ~~are~~Act ~~not~~of ~~subject~~2002, toas ~~compliance~~well ~~with~~as ~~rules~~rule ~~requiring~~changes proposed and enacted by the ~~adoption~~SEC, national securities exchanges, and the NASDAQ Stock Market as a result of ~~certain~~Sarbanes-Oxley, require implementing various measures relating to corporate governance. These measures, ~~our~~are ~~stockholders~~designed to enhance the integrity of corporate management and the securities markets and apply to securities listed on those exchanges or the NASDAQ Stock Market. We have ~~limited~~not ~~protection~~yet ~~against~~adopted ~~interested-director~~these ~~transactions,~~measures ~~conflicts~~because we are not currently required to comply with many of ~~interest~~the corporate governance provisions and ~~similar~~because ~~matters~~we chose to avoid incurring the substantial additional costs associated with voluntary compliance.

~~The~~10 ~~Sarbanes-Oxley~~Table ~~Act~~ of 2002 as well as rule changes proposed and enacted by the SEC, national securities exchanges and the NASDAQ Stock Market as a result of Sarbanes-Oxley, require the implementation of various measures relating to corporate governance. These measures are designed to enhance the integrity of corporate management and the securities markets and apply to securities that are listed on those exchanges or the NASDAQ Stock Market. Because we are not currently required to comply with many of the corporate governance provisions and because we chose to avoid incurring the substantial additional costs associated with voluntary compliance, we have not yet adopted these measures.Contents

We do not currently have independent audit or compensation committees. As a result, directors have the ability, among other things, to determine their ~~own~~ level of compensation. Until we comply with such corporate governance measures, regardless of whether such compliance is required, the absence of such standards of corporate governance may leave our stockholders without protections against interested- director transactions, conflicts of interest, and similar matters, and investors may be reluctant to provide us with funds necessary to expand our operations ~~as a result thereof~~.

We intend to comply with all corporate governance measures relating to director independence as and when required. However, we may find it very difficult or be unable to attract and retain qualified officers, directors, and members of board committees required to provide for our effective management asdue ato ~~result of~~ Sarbanes-Oxley. The enactment of Sarbanes-Oxley has resulted in a series of rules and regulations by the SEC that increase the responsibilities and liabilities of directors and executive officers. The perceived increased personal risk associated with these recent changes may make it more costly or deter qualified individuals from accepting these roles.

Item 1B - Unresolved Staff Comments

None

Item 2 -– Properties

The Company currently maintains a physical address at 2620 Regatta Dr, Suite 102, Las Vegas, NV 89128. The Company does not currently maintain any other office facilities and does not anticipate the need to maintain office facilities at any time in the foreseeable future.

Item 3 - Legal Proceedings

The Company is not a party to any pending legal proceedings, and no such proceedings are known to be contemplated.

Item 4 - Mine Safety Disclosures

Not applicable.

1311 Table of Contents

PART II

Item 5 - Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities

Market for Trading and Eligibility for Future Sale

Our common stock started trading on June 10, 2014. Our current trading symbol is “BDPT”. Currently there is only a limited, sporadic, and volatile market for our stock. The following table sets forth the high and low sales prices of our common stock as reported on www.nasdaq.com for the periods indicated. These prices represent prices between inter-dealer prices, do not include retail markups, markdowns, or commissions, and do not necessarily reflect actual transactions.

Fiscal year ended December 31, 2023	High		Low
Fiscal year ended December 31, 2024	High		Low
Quarter ended December 31, 2023		.0005		.0004
Quarter ended December 31, 2024		0.1802		0.015
Quarter ended September 30, 2023		.0003		.00024
Quarter ended September 30, 2024		0.0004		0.0002
Quarter ended June 30, 2023		.0012		.001
Quarter ended June 30, 2024		0.0006		0.0002
Quarter ended March 31, 2023		.0009		.0006
Quarter ended March 31, 2024		0.0005		0.0002
Fiscal year ended December 31, 2022		.001		.001
Fiscal year ended December 31, 2023		0.0005		0.0004
Fiscal year ended December 31, 2021		0.011		0.010
Fiscal year ended December 31, 2022		0.001		0.001

The closing price of our common stock on ~~March~~December 2331, ~~2021,~~2024 was $0.~~0006 as reported by the OTCQB Bulletin Board.~~06

The closing price of our common stock on March 21, 2025 was $0.09

Holders of Record

As of March 2221, 2024, ~~we had 972~~9,~~160~~048,~~641~~659 shares of our common stock issued and outstanding were held by approximately ~~10873~~135 stockholders of record, exclusive of shares held in street name. We also had 311,~~350,000~~167 shares of Series A preferred stock, ~~issued~~9,667 ~~and~~shares ~~outstanding~~of ~~and~~Series 2B preferred stock,~~750~~ 1,000,000 shares of Series BC preferred stock, and 68,865 shares of Series D preferred stock issued and outstanding.

Transfer Agent

Our stock transfer agent is Madison Stock Transfer LLC., ~~Their~~whose address is 2500 Coney Island Ave., Brooklyn, NY 11223. ~~Madison~~The ~~is registered by the~~ Securities and Exchange Commission registers Madison as a transfer agent, and it is wholly independent of us, with no common ownership or management.

Common Stock

The Company is authorized to issue up to 1,250,000,000 shares of common stock with a par value of $0.0001 per share.

Our Board of Directors is authorized to issue additional shares of common stock not to exceed the amount authorized by the Articles of Incorporation, on such terms and conditions and for such consideration as the Board may deem appropriate without further stockholder action.

In the event of our liquidation or dissolution, all shares of our common stock are entitled to share equally in our assets available for distribution to stockholders. However, the rights, preferences, and privileges of the holders of our common stock are subject to, and may be adversely affected by, the rights of the holders of shares of preferred stock that our Board of Directors may decide to issue in the future.

Preferred Stock

Effective ~~January~~March 2613, ~~2022~~2025, the Company is authorized to issue up to 1031,000,000 shares of preferred stock with a par value of $0.0001 per share.

As of March 2221, ~~2024~~2025, the Company has authorized 4,000,000 shares of Series A Preferred Stock, of which 311,~~350,000~~167 shares are issued and outstanding,; ~~and has authorized~~ 5,000,000 shares of Series B Preferred Stock, of which 29,~~750~~667 are issued or outstanding; 1,000,000 ~~shares~~Series C Preferred Stock, of which 1,000,000 are issued orand outstanding; and 20,000,000 Series D Preferred Stock, of which 68,865 are issued and outstanding.

14 Table of Contents

Dividend Policy

We have never declared or paid cash dividends. We currently intend to retain all future earnings for the operation and expansion of our business and do not anticipate paying cash dividends on the common stock in the foreseeable future. Any payment of cash dividends in the future will be at the discretion of our Board of Directors and will depend upon our results of operations, earnings, capital requirements, contractual restrictions and other factors deemed relevant by our directors. However, to show appreciation to our investing public, the Company did disburse a one-for-one common shares dividend in January 2025.

Table of Contents

Share Purchase Warrants

WeNo ~~have~~share ~~not~~purchase ~~issued and do not have outstanding any~~ warrants towere ~~purchase~~issued ~~shares~~during ofthe ~~our stock~~period.

Options

We have not issued and do not have outstanding any options to purchase shares of our stock.

Convertible Securities

The Company entered into a series of convertible note transactions in ~~2022and~~2022 and 2023 with PowerUp Lending Group, Ltd., a ~~Virginia~~New York-based lender and 1800 DIAGONAL LENDING, LLC. During ~~2022~~2024 ~~and early 2023,~~ these notes were paid by issuance of shares to ~~1800~~PowerUp and Diagonal Lending as follows:

1800 Diagonal Lending, LLC
	3/06/23	8,351,351
	1/03/24	44,583,333
	3/14/23	12,432,432
	1/04/24	31,927,083
	3/15/23	12,432,432
	3/26/24	48,500,000
	3/20/23	12,432,432
	3/26/24	48,500,000
	3/23/23	12,580,645
	3/27/24	37,000,000
	3/23/23	12,580,645
	3/28/24	48,500,000
	3/24/23	16,129,032
	4/01/24	56,944,444
	3/24/23	16,129,032
	4/10/22	20,013,889
	3/27/23	16,129,032
	3/27/23	13,185,484
	5/26/23	19,032,258
	5/31/23	19,032,258
	6/01/23	21,041,667
	6/02/23	21,055,556
	6/05/23	21,055,556
	6/06/23	21,055,556
	6/07/23	21,055,556
	6/07/23	21,055,556
	6/08/23	27,152,778
	12/21/2023	38,333,333
	12/26/2023	40,327,869
	12/28/2023	40,625,000

15From ~~Table~~January 1, 2024, to December 31, 2024, 335,968,749 shares of ~~Contents~~common stock were issued under these agreements. The company has not entered into any new convertible note transaction since the change in management in May 2024.

REGULATION A+ Securities

The Company filed a REG A+ securities filing in 2022, which became effective on 11/11/2022. Eight subscriptions were made in July and August 2023 as follows:

1800 Diagonal Lending, LLC
	07/10/23	25,000,000
	07/11/23	25,000,000
	07/18/23	25,000,000
	07/24/23	25,000,000
	07/26/23	25,000,000
	07/27/23	25,000,000
	08/02/23	25,000,000
	08/04/23	25,000,000

A total of 443,2050469 shares of common stock were issued under these Convertible Securities agreements during the period from January 1, 2023, to December 31, 2023. 200,000,000 shares of common stock were issued under Regulation A+ subscriptions.

On June 8, 2023, we issued a convertible note to 1800 Diagonal Lending, LLC in the amount of $47,500, on these same terms. On September 21, 2023, we issued another convertible note to 1800 Diagonal Lending, LLC in the amount of $47,500.00, on these same terms

Securities Authorized for Issuance Under Equity Compensation Plans

~~Since~~The ~~May 31, 2021, we adopted an equity compensation plan that permitted the~~ Company ~~to pay its executives with Restricted Stock Units~~ and ~~also~~the ~~provided~~CEO ~~for~~agreed ato ~~discretionary~~annual ~~pool~~compensation of ~~share~~$300,000 topayable bemonthly, ~~awarded to employees~~$25,000. ~~consultants and others~~Mr. WeKeener ~~previously~~has ~~paid~~opted ~~our~~to ~~officers~~take ~~and~~his ~~directors~~pay byin ~~direct~~preferred ~~issuance~~stock ofthus ~~restricted shares~~far. ~~Although~~As ~~the issuance~~ of ~~RSUs~~December ~~impacts~~31, ~~our~~2024, ~~financial statement as an expense item~~18,062 ~~we have not yet issued any~~ shares ~~under this Plan, and the Company has not made any award~~ of ~~restricted~~Preferred ~~shares.~~Series ~~These~~D ~~RSU~~stock ~~agreements~~ were ~~terminated~~allocated onto ~~April~~Mr. 14James Keener, ~~2022~~CEO.

~~Recent~~Per ~~Sales~~the Company’s Directors’ agreement during the term of this Agreement, the Company is to pay a Director, if the Company does not otherwise compensate the Director as an officer or ~~Issues~~employee, common stock in BDPT based upon the floating average of ~~Unregistered~~the ~~Securities~~close of the five trading days prior to the end of the month preceding the issuance. Such an Issuance is to be made within 10 days of the date earned. Shares are to be fully earned and paid for on the day of issuance. Payments to be made according to the following schedule:

WeJune ~~did~~1, ~~not~~2024, ~~sell~~$20,000.00, ~~any~~July ~~unregistered securities during the period from January~~ 1, ~~2023~~2024, to ~~and including~~ December 31, ~~2023~~2024 $5,000.00 Wemonthly. ~~issued~~A ~~442~~total of 12,~~205,460~~958 shares toof ~~1800~~Preferred ~~Diagonal~~Series ~~Lending,~~D ~~LLC~~stock towere ~~satisfy~~allocated ~~convertible~~for ~~notes,~~issuance asbetween ~~reflected~~June ~~above~~1, ~~and~~2024, ~~200~~to December 31,~~000,000~~ ~~shares~~2024 ~~for~~to ~~RegA+~~Mr ~~subscriptions~~Gimhana Dissanayake.

Purchases of Equity Securities by the Issuer and Affiliated Purchases

Neither we nor any “affiliated purchaser”, as that term is defined in Rule 10b-18(a)(3) under the Exchange Act, repurchased any of our common stock or other securities during the period from January 1, 2021 to December 31, 2021.

Item 6 - Selected Financial Data

Not applicable

Item 7 - Management’s Discussion and Analysis of Financial Condition and Results of Operations

(1) Caution Regarding Forward-Looking Information

Certain statements contained in this annual filing, including, without limitation, statements containing the words “believes”, “anticipates”, “expects” and words of similar import, constitute forward-looking statements. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements.

1613 Table of Contents

Given these uncertainties, readers of this Form 10-K and investors are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future events or developments.

(2) General

The Company’s History

On January 10, 2014, the SEC notified the Company that the registration statement was effective and on July 9, 2014, the Company’s shares commenced trading in the Over-the-Counter market under the trading symbol BDPT.

On March 31, 2017, the Company filed a Form 15-15D with the SEC, terminating its status as an SEC-reporting company; it was current in its Continuous Disclosure obligations at that time. The Company continued to provide financial and other reports to shareholders and the public by means of the Alternative Reporting System operated by OTC Markets Group, Inc. Its shares continued to trade in the ~~OTC~~OTCMarkets, ~~market~~ and it also continued to execute its business plan.

On September 11, 2019, the Company appointed Robert Ellis as President and Ron Lambrecht as Chief Financial Officer. Dr. Jacobs remained as Chief Executive Officer.

On ~~January~~March 2618, 2022, the ~~Board~~Company offiled ~~Directors~~Form ~~exercised~~1-A ~~its~~with ~~authority under~~ the ~~Delaware~~Securities ~~General Corporations Law to establish its Series B Preferred Stock. The Series B has enhanced voting~~ and ~~conversion~~Exchange ~~privileges~~Commission ~~and~~covering ~~can~~a beplan ~~used~~to bysell ~~the~~up ~~Company~~ to ~~acquire~~200,000,000 ~~ownership~~shares of ~~intellectual~~common ~~property~~stock ~~rights~~for ~~and~~prices ~~other~~between ~~assets~~.005 Onand ~~this~~.01 ~~same~~per ~~day,~~share. ~~the~~This ~~Board~~was ofamended ~~Directors~~on ~~authorized~~October an7 ~~increase~~2022 ~~in the Company’s authorized common stock from 200,000,000~~ to ~~750~~250,000,000; ~~this~~shares ~~increase~~of ~~received~~common ~~the~~stock ~~consent~~at of the ~~holders~~price of ~~a majority of the Company’s common shares~~0.001.

~~Effective~~On February 228, ~~2022~~2023, the ~~Company~~Board ~~acquired~~of Directors exercised its authority under the ~~exclusive~~Delaware ~~option~~General Corporation Law to ~~purchase~~increase ~~U.S.~~the ~~Patent~~Company’s ~~No.~~authorized 9common stock from 750,~~783~~000,~~432B~~000 ~~(the~~to ~~“Patent”)~~1,250,000,000; ~~covering~~this ~~technology~~holders ~~used~~of ina ~~enhancing~~majority of the ~~capability~~Company’s ofshares ~~water~~consented to ~~hold~~the ~~significantly larger amounts of oxygen~~increase.

On ~~March~~May 1815, ~~2022~~2024, ~~the~~Dr. ~~Company~~Edward ~~filed~~Jacobs aretired ~~Form~~from ~~1-A with~~ the ~~Securities~~Company and ~~Exchange~~was ~~Commission~~succeeded ~~covering~~by aMr. ~~plan~~James toE. ~~sell~~Kneer upas toChairman ~~200,000,000 shares of common stock for prices between .005~~ and CEO.01 ~~per~~As ~~share.~~of ~~This~~May ~~was~~27, ~~amended~~2024, onMr. ~~October~~Gimhana 7Dissanayake ~~2022~~joined tohim ~~250,000,000~~as ~~shares~~a Director of ~~common stock at~~ the ~~price of 0~~Company.~~001.~~

~~June~~On 2October ~~2022. BioAdaptives~~28, ~~sponsored a COVID Long Haul Survey conducted by independent medical researcher~~2024, ~~Regina~~the ~~Sutton,~~Board ~~M.D.,~~unanimously ~~Gilbert,~~resolved ~~Arizona.~~to ~~Dr.~~proceed ~~Sutton,~~with ~~will~~a ~~study~~reverse ~~the~~split ~~effects~~ of ~~Bioadaptives’~~1 ~~nutraceuticals~~for in300 ~~the management of chronic symptoms associated with COVID – 19 infections~~shares.

On ~~February~~December 283, ~~2023~~2024, the Board ofapproved ~~Directors~~a ~~exercised~~One-for-One ~~its~~Stock ~~authority~~Dividend ~~under the Delaware General Corporation Law~~ to ~~increase the Company’s authorized common stock from 750,000,000 to 1,250,000,000; this~~ holders of acommon ~~majority of the Company’s shares consented to the increase~~stock.

On14 ~~September~~Table 8,of ~~2023, the Company registered its Livestock Impact Division as a wholly owned subsidiary in Nevada with 200,000,000 shares authorized and 10,000,000 preferred shares.~~Contents

On October 11, 2023, the Company filed a Form 1-A with the Securities Exchange Commission covering a plan to sell up to 250,000,000 shares of common stock for prices between $0.001-0.003. This filing is ongoing.

17 Table of Contents

The Company’s Business

Overview

BioAdaptives’ core business is toinvestigating, ~~investigate~~marketing, ~~market~~ and ~~distribute~~distributing natural plant, ~~algal~~fungi, and ~~mushroom~~algal-based products and medical devices that improve health and wellness for humans and animals,. ~~with~~The ancompany ~~emphasis~~emphasizes onweight control, pain relief, ~~anti-viral~~antiviral function, and anti-aging properties.

~~Effective~~The ~~November~~Company’s ~~15,~~current ~~2021,~~products ~~the~~in ~~Company~~development ~~entered~~include ~~into~~ a ~~marketing~~weight ~~agreement~~management ~~for~~supplement anin ~~FDA-cleared~~a ~~medical~~Human ~~device~~Clinical Trial, ~~the~~Zeranovia™. ~~Lung Flute~~Zeranovia™, ~~which~~is made of natural ingredients and uses proprietary methods of optimizing the ~~Company~~availability ~~called~~of ~~Lung~~nutrients ~~Cleanser™~~in foods and beverages. The ~~Company~~trials isare ~~also~~proceeding ~~exploring~~positively, ~~agreements~~ with ~~other~~consistent ~~medical~~weight ~~device~~loss ~~manufacturers;~~with ~~the~~minimal ~~owners~~side ofeffects. ~~intellectual~~Zeranovia™ ~~property~~empowers ~~relating~~users to ~~medical~~lose ~~devices~~weight ~~and~~while ~~processes;~~maintaining ~~and~~more ~~marketing~~lean ~~companies~~muscle ~~associated~~mass. ~~with~~Based ~~these~~on ~~manufacturers~~current ~~and~~results, ~~owners~~Zeranovia™ is expected to be introduced commercially in the second quarter of 2025.

~~The~~Xcellara™ ~~Company’s~~regenerative ~~current~~stem ~~products~~cell ~~include~~activator ~~dietary~~is ~~supplements using natural ingredients and proprietary methods of optimizing the availability of nutrients~~ in ~~foods~~production and ~~beverages.~~is ~~Human~~expected ~~products are designed~~ to ~~aid~~be ~~memory,~~sold ~~cognition~~commercially ~~and focus; assist~~ in ~~sleep~~April ~~and fatigue reduction; provide pain relief and healing; and improve overall emotional and physical wellness~~2025. ~~Our current product line for humans includes PluriPain®, PrimiLungs~~PawPa™~~,SleepEZ™,~~ ~~MindNMemory™~~Regen, ~~Cell~~the ~~Rejuven™~~canine ~~and~~treat ~~ProteinNMore™~~stem .cell Weactivator, ~~also~~will ~~market~~be ~~the~~available ~~Lung~~for ~~Flute™~~delivery ~~and PrimiLungs™ products~~ in ~~our~~early ~~Lung~~April ~~Armor™~~2025 ~~packaging,~~with ~~emphasizing~~ the ~~anti-viral~~first ~~properties~~finished ofproduct ~~the~~delivered ~~nutraceutical~~to ~~and general respiratory health benefits from use of~~ the ~~device.~~warehouse ~~Pluripain®~~on isMarch a28, ~~fast acting long lasting all natural pain relief formulation~~2025. ~~MindnMemory~~ PawPa™ isRegen asupports ~~nootropic formulation that enhances memory~~anti-aging, ~~focus~~wellness, ~~mental clarity~~ and ~~endurance;~~overall ~~PrimiSleep™ is a natural soporific that aids relaxation and sleep quality~~responsiveness. ~~Cell~~These ~~Rejuven™~~formulations ~~increases~~are ~~Energy~~based ~~and~~upon ~~Mobility~~extensive ~~and~~trials ~~resistance~~on tohumans, ~~stress~~dogs, ~~activates~~horses, ~~primitive cells~~hogs, ~~improves wound healing~~ and ~~promotes hair and nail growth~~mice. ~~ProteinNMore™~~The ~~aids~~canine inproducts ~~rapidly~~are ~~building~~all ~~lean bulk muscle, promotes muscle contractility and strength as well as helps~~ in ~~improving blood flow. We acquired~~ the ~~licenses~~form ~~for~~of ~~these products during 2021 and 2022~~treats, ~~and~~making ~~have~~delivery ~~commenced marketing activities for these products. Sales of the Lung Cleanser™ have not met our expectations~~ and wedosing ~~anticipate~~very ~~concentrating~~simple ~~in marketing this device through wholesale channels~~ and ~~on Amazon instead~~effective.

~~Our~~At ~~animal~~the ~~products~~request ~~include~~of ana ~~Equine~~member ~~All-in-One™~~of ~~and~~the ~~Equine~~BioAdaptives ~~All-In-One~~Board ~~Plus™~~of ~~formulation~~Advisors, ~~which~~BioAdaptives wedeveloped ~~market~~an toadvanced ~~trainers~~nootropic, ~~horse owners and boarding stables~~MyndMed™, ~~and~~it afocuses ~~Canine~~on ~~All-in-One™~~diverse ~~that~~pathways, wedelivering ~~market~~acetylcholine ~~directly~~(focus), todopamine ~~consumers.~~(mood), ~~Anecdotal~~GABA ~~and~~(calm), ~~testimonial~~antioxidants ~~reports are that the equine products provide significant relief from exercise induced pulmonary hemorrhaging~~(protection), asand ~~well~~energy as(increased ~~improved~~mitochondria) ~~coat~~while ~~and~~avoiding ~~mane~~tolerance ~~appearance~~ and ~~hoof~~extending ~~health~~impact. ~~The~~MyndMed™ ~~canine~~is ~~products~~designed ~~have~~to ~~demonstrated~~improve ~~significant~~memory, ~~rejuvenating~~learning, ~~benefits~~cognitive ~~for~~enhancement, ~~older~~mood ~~dogs~~support, ~~improving~~neuroprotection, ~~overall~~neuroplasticity, ~~appearance~~ and ~~energy~~stress ~~levels~~resilience. ~~Effective April 2023, FCBR Therapy Division has been appointed its exclusive Distributor for all of the LiveStock Impact Inc~~It’s ~~products,~~designed ~~as such the Company also negotiated with the supplier~~ for ~~the~~a ~~exclusive~~fast ~~marketing~~increase ~~rights~~of tofocus ~~these~~and ~~products~~clarity ~~from~~today ~~the~~and ~~non~~long-~~exclusive~~term ~~license~~benefits itfor ~~has~~memory ~~held~~and ~~since~~brain ~~June~~health ~~2022.~~for Inweeks ~~this~~and ~~first quarter of the exclusive wholesale agreement, its wholesale volume has surpassed the past 9~~ months ~~total by 400%~~. ~~Granted~~It ~~due~~works towith ~~the~~your ~~switch~~biology ~~from retail~~ to ~~wholesale~~improve ~~the~~your ~~margins are much tighter, but we believe in 2024, the expanded sales will greatly benefit this wholly owned subsidiary and justifies its eventual independence~~mind.

~~The~~We ~~Company~~continue isresearching ~~also~~and ~~negotiating~~developing ~~distribution~~new ~~rights~~nutraceutical ~~to three additional human~~ products: ~~Pluripain~~for ~~PMS™,~~humans ~~which~~and isanimals ~~designed~~ to ~~help~~solve ~~manage~~problems ~~the~~and ~~symptoms~~deliver ~~associated with~~ the ~~menstrual cycle; VeganHepplus™, a liver support supplement; as well as NaturaComplete™, an All~~best-Inin-~~One~~class ~~dietary~~products. ~~supplement~~Our ~~formula~~products ~~with~~are ~~over 70 vitamins~~unique, ~~mineral~~well-designed, ~~amino~~ and ~~fatty~~proven ~~acids, trace minerals and other nutrients~~ to ~~support~~bring ~~general~~benefits, ~~health~~not ~~and~~just ~~obesity~~copies ~~management~~of ~~activities.~~other ~~These three new~~ products ~~are expected to be in market within first six months of 2024~~.

Effective February 2, 2022, the Company acquired the option to purchase U.S. Patent No. 9,783,432B (the “Patent”), covering technology used in enhancing the capability of water to hold significantly larger amounts of oxygen. Since June 6, 2022, we entered into a services agreement with Wildpack Beverages in Las Vegas, Nevada to co-pack a pilot run (1333 cases) of this Product. However, since technical problems prevented completion of the planned pilot run, after trying to source a manufacturing facility to co-pack a pilot run had failed to materialize, the Company is expected to not take up the option of purchasing this technology.

Since March 2023, the Company has been studying the FitYourOut,fit® system, a low-cost AI smart phone app body composition tracking system to detect unwanted muscle mass loss reported with obesity management and also fat loss. In January 2024, BioAdaptives signed a Distributor’s agreement with PIXELCANDO SL to distribute this product in North America.

Since the latter part of March, the Company has started to explore the Botanical Drugs sphere. We acquired the non-exclusive licenses from Dr. Yaguang Liu, LY Research for Glucose Management, Eye Health due to Myopia and Presbyopia and a resveratrol product. Dr Liu has had over 40 years of research and development in the Botanical Drugs area. We are exploring the opportunities in deploying these patented products for nutraceutical use for human and animal initially. With Botanical drug interest being migrated to LiveStock Impact, Inc, the wholly owned subsidiary, Dr Liu has also migrated his directorship from BioAdaptives to LiveStock Impact, Inc.

We are reliant on direct web sales of the nutraceutical lines for humans products and none of which has produced any significant revenue yet. Whereas LiveStock Impact, Inc appointed an exclusive distributor and has increased its sales volume by 400%. Because of this, we are now exploring the wholesale and white label markets for the human supplement sales. We have very limited experience in marketing and have yet to develop reliable sales expectations and forecasting.

18 Table of Contents

(3) Results of Operations

The Company has ~~recognized~~minimal revenues for the years ~~ended~~ending December 31, ~~2022~~2024, and December 31, 2023, of $1712,~~176~~669 and $28,565, respectively. On May 21, 2024, Mr. James Keener was elected to be the CEO of BioAdaptives on May 15, 2024. After thoroughly analyzing BioAdaptives’ product line, Keener canceled all dietary supplement products. Keener had been working with his team for over one year on developing meaningful dietary supplements. This resulted in no revenue from May 15, 2024, to the present.

InOne ~~conjunction~~of ~~with~~ the ~~Company’s~~primary ~~business~~products ~~plan,~~Keener asbrought ~~discussed~~to inthe ~~Item~~table Iwas ofthe ~~this~~Weight ~~document,~~Management ~~the~~product ~~Company~~Zeranovia™. ~~has~~Based ~~expended~~on ~~considerable~~strong ~~effort~~relationships ~~and~~with ~~financial~~others, ~~resources~~Keener was able to ~~the~~obtain ~~implementation~~an ofInstitutional ~~its~~Review ~~business~~Board ~~plan~~(IRB) approval for the product. ~~The~~It ~~Company~~is ~~incurred~~now ~~operating~~in ~~expenses~~Human ofClinical ~~$239~~Trials,~~740,~~ ~~which~~and ~~required~~results ~~cash~~show ~~payments~~it ofis ~~$211,566,~~ready ~~which~~for ~~was~~market. ~~principally~~A ~~funded~~strong ~~through~~competitor ~~convertible~~to ~~debt~~GLP-1 and ~~RegA+~~GIP ~~subscriptions~~agonists, asit ~~disclosed~~has inbeen ~~the~~shown ~~accompanying~~to ~~financial~~increase ~~statement~~Cholecystokinin ~~footnotes.~~(CCK) ~~The~~an ~~balance~~important ofweight ~~the~~loss ~~operating~~peptide. ~~expenses~~Zeranovia™ ~~was~~is ~~for~~expected ~~activities~~to ~~that~~be ~~did~~a ~~not~~successful ~~require~~product ~~cash~~in ~~payments~~2025, ~~including~~with ~~stock-based~~the ~~compensation~~first ~~and~~revenue afor ~~discount~~the ~~for~~new ~~amortization~~product ofline ~~debt~~coming in during the second quarter.

~~Earnings~~Three ~~(Loss)~~new ~~per~~and ~~share~~proven ~~for~~products will enter the ~~respective~~retail ~~years~~market ~~ended~~in ~~December~~the ~~31,2022~~second ~~and~~quarter: ~~December~~Xcellara™ ~~31,~~(being ~~2023,~~bottled ~~were~~in ~~$(0.01~~Las Vegas now), ~~and~~PawPa™ Regen (~~0.00~~the Finished product was recently delivered to our warehouse), ~~respectively,~~MyndMed™ ~~based~~(currently onin ~~the~~production), ~~weighted-average~~and ~~shares~~Zeranovia™. ~~issued~~It ~~and~~is ~~outstanding~~expected atthat ~~the~~they ~~end~~will ofbe ~~each~~manufactured ~~respective~~in ~~period~~12 weeks.

WeIn ~~anticipate~~conjunction ~~that~~with ~~future~~the ~~expenditure~~Company’s ~~levels~~business ~~will~~plan, ~~remain~~as ~~relatively~~discussed ~~consistent~~in ~~until~~Item ~~such~~I ~~time~~of ~~that~~this document, the Company ~~fully~~has ~~implements~~expended ~~its~~considerable ~~current~~effort ~~business~~and ~~plan,~~financial atresources ~~which~~to ~~time~~implement ~~the~~its business plan. The Company’s incurred operating expenses ~~and~~of ~~working~~$429,026, ~~capital~~which ~~requirements~~required ~~may~~cash ~~increase~~payments ~~significantly.~~of ~~The~~$254,119, ~~Company~~which ~~does~~was ~~not~~principally ~~expect~~funded tothrough ~~generate~~convertible ~~any~~debt ~~meaningful~~as ~~revenue~~disclosed orin ~~incur~~the ~~operating~~accompanying ~~expenses~~financial ~~for~~statement ~~purposes~~footnotes ~~other~~and ~~than~~advances ~~fulfilling~~from ~~the~~shareholders. The ~~obligations~~operating ofexpenses awere ~~reporting~~for ~~company~~activities ~~under~~that ~~the~~did ~~Exchange~~not ~~Act~~require ~~unless~~cash ~~and~~payments, ~~until~~including ~~such~~stock-based ~~time~~compensation ~~that~~and ~~the~~a ~~Company~~discount ~~begins~~for ~~meaningful~~the ~~operations~~amortization of debt.

Earnings (Loss) per share for the respective years ended December 31, 2023, and December 31, 2024, were $0.11 and $0.12, respectively, based on the weighted-average shares issued and outstanding at the end of each respective period.

We anticipate that future expenditure levels will remain relatively consistent until the Company fully implements its current business plan, at which time the Company’s expenses and working capital requirements may increase significantly. The Company does not expect to generate any meaningful revenue or incur operating expenses for purposes other than fulfilling the obligations of a reporting company under the Exchange Act unless and until such time that the Company begins meaningful operations.

(4) Plan of Business

Subject to financing and various regulatory approvals, the Company intends to 1) market its existing products as described herein; 2) continue conducting research and investigation activities to identify new products or markets and improve its existing products and marketing; and 3) seek strategic or complimentary acquisitions in its current market space or, if indicated, others. There is no guarantee that the Company will be able to ~~successfully~~ implement this business plan successfully or that if implemented, said plan will be successful.

Table of Contents

(5) Liquidity and Capital Resources

On December 31, ~~2022~~2023 and ~~2023~~2024, ~~respectively,~~ the Company had working capital of approximately $~~(0)~~88,557 and $~~(0);~~261,885, ~~inclusive~~including of all related party accounts receivable, accrued expenses, and line-of-credit notes payable.

It is the belief of management that our current finance partners, shareholders, and the proceeds from our ~~potential~~sales ~~Reg.~~of A+Preferred ~~offering~~D will be able to provide sufficient working capital necessary to support and preserve the integrity of the corporate entity. However, there is no legal obligation for either management or significant stockholders to provide additional future funding, and we cannot be assured as to the success of our offering. Further, the Company is at the mercy of future economic trends and business operations. Consequently, there is substantial doubt about the Company’s ability to continue as a going concern.

The Company’s need for working capital may change dramatically asdue ato ~~result of~~ any future business transaction.

There can be no assurance that the Company will identify or enter into any business transaction in the future. Further, there can be no assurance that the Company would besuccessfully ~~successful~~consummate ~~in consummating~~ any acquisition on favorable terms or that it will ~~be able to~~ profitably manage the business, product, technology, or company it acquires.

The Company has no current plans, proposals, arrangements, or understandings ~~with~~regarding ~~respect to~~ the sale or issuance of additional securities prior to the location of a potential business transaction. Accordingly, there can be no assurance that sufficient funds will be available to the Company to ~~allow it to~~ cover the expenses related to such activities.

~~Regardless~~Whether ~~of whether~~ the Company’s cash assets prove ~~to be~~ inadequate to meet ~~the~~its ~~Company’s~~ operational needs, the Company might seek to compensate service providers ~~of services~~ by ~~issuances~~issuing of stock in lieu of cash.

(6) Critical Accounting Policies

Our financial statements and related public financial information are based on ~~the~~applying ~~application of~~ accounting principles generally accepted in the United States (“GAAP”). GAAP requires ~~the~~using ~~use of~~ estimates;, assumptions, judgments, and subjective interpretations of accounting principles that ~~have an~~ impact on the assets, liabilities, revenue, and expense amounts reported. These estimates can also affect supplemental information contained in our external disclosures, including information regarding contingencies, risk, and financial condition. We believe our use of estimates and underlying accounting assumptions adhere to GAAP and are consistently and conservatively applied. We base our estimates on historical experience and on various other assumptions that we believe toare be reasonable under the circumstances. Actual results may differ materially from these estimates under different assumptions or conditions. We continue to monitor significant estimates made ~~during~~while ~~the~~preparing ~~preparation of~~ our financial statements.

Our significant accounting policies are summarized in Note 2 of our financial statements. While all these significant accounting policies impact on our financial condition and results of operations, we view ~~certain~~sure of these policies as critical. Policies determined to be critical are those policies that have the most significant impact on our financial statements and require management to use a greater degree of judgment and estimates. Actual results may differ from those estimates. Our management believes that given current facts and circumstances, it is unlikely that applying any other reasonable judgments or estimate methodologies would cause an effect on our results of operations, financial position, or liquidity for the periods presented in this report.

Item 7A - Quantitative and Qualitative Disclosures about Market Risk

Not applicable

19Item ~~Table~~8 of- ~~Contents~~Financial Statements and Supplementary Data

~~Item~~16 8Table -of ~~Financial Statements and Supplementary Dat~~Contents

BIOADAPTIVES, INC

CONSOLIDATED FINANCIAL STATEMENTS

FOR THE YEARS ENDED DECEMBER 31, ~~2022~~2024, AND ~~2021~~2023

TABLE OF CONTENT	PAGE
Report of Independent Registered Public Accounting Firm (PCAOB ID: 5041)		21
Report of Independent Registered Public Accounting Firm		F-2
Consolidated Balance Sheet		22F-3
Consolidated Statements of Operations		23F-4
Consolidated Statements of Stockholders’ Deficit		24F-5
Consolidated Statements of Cash Flows		25F-6
Notes to Consolidated Financial Statements		26F-7

20F-1 Table of Contents

Report of Independent Registered Public Accounting Firm

ToThe ~~the~~Board ~~shareholders and the board~~ of ~~directors~~Directors ofand ~~BioAdaptives,~~Stockholders ~~Inc.~~of

BIOADAPTIVES, INC.

Opinion on the Financial Statements

We have audited the accompanying consolidated balance sheets of BioAdaptives, Inc. (the ‘Company’) as of December 31, ~~2023~~2024 and ~~2022~~2023, and the related consolidated statements of operations, changes in stockholders’ equity/ (deficit), and cash flows for ~~the~~each ~~years~~of ~~then ended, and~~ the ~~related~~two ~~notes~~years ~~(collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly,~~ in ~~all material respects,~~ the ~~financial~~period ~~position~~ended ~~of the Company as of~~ December 31, ~~2023~~2024 and ~~2022~~2023, and the ~~results~~related ofnotes ~~its~~(collectively ~~operations~~referred ~~and~~to ~~its~~as ~~cash flows for~~ the ~~years~~“financial ~~then ended, in conformity with accounting principles generally accepted in the United States~~statements”).

~~Substantial~~In ~~Doubt~~our ~~about~~opinion, the ~~Company’s~~consolidated ~~Ability~~financial tostatements ~~Continue~~present fairly, in all material respects, the consolidated financial position of the Company as aof ~~Going~~December ~~Concern~~31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024 and 2023, in conformity with accounting principles generally accepted in the United States of America.

~~The~~Going accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3 to the financial statements, the Company has suffered recurring losses from operations and has a significant accumulated deficit. In addition, the Company continues to experience negative cash flows from operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern. Management’s plans in regard to these matters are also described in Note 3. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.Concern

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 3, the Company suffered an accumulated deficit of $(9,168,906), net loss of $(904,761) These conditions raise substantial doubt about the Company’s ability to continue as a going concern. These financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our ~~audit~~audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the ~~audit~~audits to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our ~~audit~~audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our ~~audit~~audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our ~~audit~~audits ~~provides~~provide a reasonable basis for our opinion.

~~/S/~~Critical BFAudit ~~Borgers CPA PC~~Matters

BFCritical ~~Borgers~~audit ~~CPA~~matters PCare matters arising from the current period audit of the financial statements that were communicated or required to be communicated to the audit committee and that: (~~PCAOB~~1) IDrelate ~~5041~~to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. Communication of critical audit matters does not alter in any way our opinion on the financial statements taken as a whole and we are not, by communicating the critical audit matters, providing separate opinions on the critical audit matter or on the accounts or disclosures to which they relate.

WeGoing ~~have~~Concern ~~served~~Uncertainty as– ~~the~~See ~~Company’s~~also ~~auditor~~Going ~~since~~Concern ~~2018~~Uncertainty explanatory paragraph above:

~~Lakewood~~As described in Note 3 to the consolidated financial statements, COthe Company has significant operating losses and a working capital deficiency. The ability of the Company to continue as a going concern is dependent on obtaining additional working capital funding from the sale of equity and/or debt securities to execute its plans and continue operations. These conditions raise substantial doubt about the Company’s ability to continue as a going concern.

~~April~~The 9,procedures ~~2024~~performed to address the matter included.

21■ ~~Table~~We inquired of ~~Contents~~executive officers, and key members of management, of the Company regarding factors that would have an impact on the Company’s ability to continue as a going concern, ■ We evaluated management’s plan for addressing the adverse effects of the conditions identified, including assessing the reasonableness of forecasted information and underlying assumptions by comparing to actual results of prior periods and actual results achieved to date, and utilizing our knowledge of the entity, its business and management in considering liquidity needs and the Company’s ability to generate sufficient cash flow, ■ We assessed the possibility of raising additional debt or credit, ■ We evaluated the completeness and accuracy of disclosures in the consolidated financial statements.

/S/ Boladale Lawal

BOLADALE LAWAL & CO.

(Chartered Accountants)

(PCAOB ID 6993)

Lagos, Nigeria

We have served as the Company’s auditor since 2024.

April 15, 2025

F-2

Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED BALANCE SHEETS

	December 31,			December 31,
	2023			2022
	2024			2023
ASSETS
Current Assets:
Cash	$	60137,~~776~~470		$	2560,~~405~~776
Marketable securities		-			42
Inventory		19,115			15,281
Inventory		15,281			8,877
Security deposit		2,500			2,500
Security deposit		2,500
Prepaid expense		100,000			10,000
Prepaid expense		10,000			-
Other receivable		2,800			-
Total Current Assets		88261,~~557~~885			3488,~~324~~557
License and patent, net		~~15,441~~-			215,~~990~~441
TOTAL ASSETS	$	~~103~~261,~~998~~885		$	37103,~~314~~998
LIABILITIES AND STOCKHOLDERS’ DEFICIT
Current Liabilities:
Accounts payable and accrued liabilities		~~443~~179,~~579~~428			~~409~~443,~~920~~579
Derivative liabilities		~~977~~1,~~872~~053,249			~~686~~977,~~856~~872
Current portion of convertible notes - net of discount of $52,592 and $7,647		321,658			381,793
Convertible notes - net of discount of $0 and $52,592		311,000			321,658
Note payable - related party		7,520			10,246
Notes Payable		32,096			-
Total Current Liabilities		1,750,629			1,488,815
Note payable - related party					7,520
Total Liabilities		1,750,629			1,488,815
Stock Payable		150,000			-
Total Current Liabilities		1,725,803			1,750,629
Total Liabilities		1,725,803			1,750,629
Stockholders’ Deficit:
Preferred stock, ($0.0001 par value, 10,000,000 shares authorized;
Series A Preferred Stock 4,000,000 shares designated; 2,850,000 and 1,600,000 issued and outstanding, respectively		285			160
Series A Preferred Stock 4,000,000 shares designated; 11,167 and 9,500 issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		1			1
Series B Preferred Stock 5,000,000 shares designated; 2,250,000 and 0 share issued and outstanding, respectively		225			-
Series B Preferred Stock 5,000,000 shares designated; 9,667 and 7,500 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		1			1
Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 895,760,225 and 252,554,765 shares issued and outstanding, and 10,000 issuable, respectively)		89,576			25,255
Series C Preferred Stock 1,000,000 shares designated; 1,000,000 and 0 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		100			-
Additional paid-in capital		6,527,428			6,074,763
Series D Preferred Stock 20,000,000 shares designated; 72,687 and 0 share issued and outstanding as of December 31, 2024 and December 31, 2023, respectively		7			-
Accumulated deficit		(8,264,145	)		(7,551,679	)
Common stock ($0.0001 par value, 1,250,000,000 shares authorized; 8,215,426 and 5,971,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, and 66 issuable, respectively)		821			597
Total Stockholders’ Deficit		(1,646,631	)		(1,451,501	)
Additional paid-in capital		7,704,343			6,616,915
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	103,998		$	37,314
Subscription receivable		(5,885	)		-
Accumulated deficit		(9,163,306	)		(8,264,145	)
Total Stockholders’ Deficit		(1,463,918	)		(1,646,631	)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$	261,885		$	103,998

The accompanying notes are an integral part of these consolidated financial statements.

22F-3 Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

	Years ended
	Year ended
	December 31,
	2023			2022
	2024			2023
Revenues	$	2812,~~565~~669		$	1728,~~176~~565
Cost of revenue		178,~~746~~639			1017,~~050~~746
Gross Profit		104,~~819~~030			710,~~126~~819
Operating Expenses
General and administrative		~~101~~335,~~478~~306			~~254~~101,~~119~~478
Professional fees		~~110~~169,~~088~~523			~~112~~110,~~759~~088
Amortization of license and patent		28,174			62,148
Impairment of inventory		81,350			-
Total Operating Expenses		239,740			429,026
Amortization and impairment loss of license and patent		19,941			28,174
Loss from operations		(228,921	)		(421,900	)
Total Operating Expenses		606,120			239,740
Loss from operations		(602,090	)		(228,921	)
Other Income (Expense)
Unrealized gain (loss) on marketable securities		(42	)		(148	)
Other income		4,950			-
Interest expense		(162,891	)		(289,121	)
Unrealized loss on marketable securities		-			(42	)
Change in fair value of derivative liabilities		(307,412	)		(184,401	)
Interest expense		(91,978	)		(162,891	)
Loss on settlement of debt		(13,200	)		-
Change in fair value of derivative liabilities		(210,043	)		(307,412	)
Total Other Expense		(483,545	)		(473,670	)
Loss on settlement of debt		-			(13,200	)
Loss before income taxes		(712,466	)		(895,570	)
Total Other Income (Expense)		(297,071	)		(483,545	)
Net Loss	$	(712,466	)	$	(895,570	)
Loss before income taxes		(904,761	)		(712,466	)
Net Loss	$	(899,161	)	$	(712,466	)
Net Loss Per Common Share:
Basic and Diluted	$	(0.0011	)	$	(0.0112	)
Weighted Average Number of Common Shares Outstanding:
Basic and Diluted		~~559~~8,~~069~~215,~~032~~426			~~106~~5,~~011~~971,~~449~~728

The accompanying notes are an integral part of these consolidated financial statements.

23F-4 Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENT OF STOCKHOLDERS’ DEFICIT

	Series A				Series B								Additional
																							Additional
	Preferred stock				Preferred stock				Common stock				paid-in		Accumulated
	Series A Preferred stock				Series B Preferred stock				Series C Preferred stock				Series D Preferred stock					Common stock					paid-in		Subscription			Accumulated
	Shares		Amount		Shares		Amount		Shares		Amount		~~capital~~Shares		~~Deficit~~Amount			~~Total~~Shares			Amount		capital		receivable			Deficit			Total
Balance, December 31, 2021		1,600,000	$	160		-	$	-		50,819,780	$	5,082	$	5,557,828	$	(6,656,109	)	$	(1,093,039	)
Balance, December 31, 2022		5,333	$	1		-	$	-		-	$	-		-	$	-			1,683,704		$	168	$	6,100,009	$	-		$	(7,551,679	)	$	(1,451,501	)
Common stock issued for conversion of debt		-		-		-		-		201,734,985		20,173		501,506		-			521,679
																										-
Debts forgiveness - related party		-		-		-		-		-		-		10,000		-			10,000
Series A preferred stock issued for license fee		4,167		-		-		-		-		-		-		-			-			-		22,625		-			-			22,625
Warrant issued for Patent’s acquisition		-		-		-		-		-		-		5,429		-			5,429
Series B preferred stock issued for license fee		-		-		5,000		1		-		-		-		-			-			-		17,999		-			-			18,000
Net loss for the period		-		-		-		-		-		-		-		(895,570	)		(895,570	)
Series B preferred stock issued for settlement of debt - related party		-		-		2,500		-		-		-		-		-			-			-		16,500		-			-			16,500
Balance, December 31, 2022		1,600,000	$	160		-	$	-		252,554,765	$	25,255	$	6,074,763	$	(7,551,679	)	$	(1,451,501	)
Common stock issued for cash		-		-		-		-		-		-		-		-			1,333,328			133		177,967		-			-			178,100
Series A preferred stock issued for license fee		1,250,000		125		-		-		-		-		22,500		-			22,625
Common stock issued for conversion of debt		-		-		-		-		-		-		-		-			2,954,696			296		281,815		-			-			282,111
Series B preferred stock issued for license fee		-		-		1,500,000		150		-		-		17,850		-			18,000
Net loss for the period		-		-		-		-		-		-		-		-			-			-		-		-			(712,466	)		(712,466	)
Series B preferred stock issued for settlement of debt - related party		-		-		750,000		75		-		-		16,425		-			16,500
Balance, December 31, 2023		9,500	$	1		7,500	$	1		-	$	-		-	$	-			5,971,728		$	597	$	6,616,915	$	-		$	(8,264,145	)	$	(1,646,631	)
Common stock issued for cash		-		-		-		-		200,000,000		20,000		158,100		-			178,100
Series A preferred stock issued for license fee		1,667		-		-		-		-		-		-		-			-			-		1,500		-			-			1,500
Common stock issued for conversion of debt		-		-		-		-		443,205,460		44,321		237,790		-			282,111
Series B preferred stock issued for license fee		-		-		1,667		-		-		-		-		-			-			-		3,000		-			-			3,000
Net loss for the period		-		-		-		-		-		-		-		(712,466	)		(712,466	)
Series B preferred stock issued for settlement of debt - related party		-		-		500		-		-		-		-		-			-			-		1,500		-			-			1,500
Balance, December 31, 2023		2,850,000	$	285		2,250,000	$	225		895,760,225	$	89,576	$	6,527,428	$	(8,264,145	)	$	(1,646,631	)
Series C preferred stock issued for purchase of inventory		-		-		-		-		1,000,000		100		-		-			-			-		59,900		-			-			60,000
Series D preferred stock issued for conversion of common stock		-		-		-		-		-		-		50,000		5			-			-		299,995		(5885	)		-			294,115
Series D preferred stock issued for compensation		-		-		-		-		-		-		22,687		2			-			-		208,869		-			-			208,871
Common stock issued for conversion of debt		-		-		-		-		-		-		-		-			2,239,794			225		202,419		(5,885	)		-			202,643
Reverse split adjustment Debt Forgiveness		--		--		--		--		--		--		--		--		04				-		310,245		-			-			310245
Net loss for the period		-		-		-		-		-		-		-		-			-			-		-		-			(899,161	)		(899,161	)
Balance, December 31, 2024		11,167	$	1		9,667	$	1		1,000,000	$	100		72,687	$	7			8,215,426		$	8,221	$	7,704,343	$	(5,885	)	$	(9,163,306	)	$	(1,463,918	)

The accompanying notes are an integral part of these consolidated financial statements.

24F-5 Table of Contents

BIOADAPTIVES, INC.

CONSOLIDATED STATEMENTS OF CASH FLOW

	Years ended
	Year ended
	December 31,
	2023			2022
	2024			2023
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$	(~~712~~899,~~466~~161	)	$	(~~895~~712,~~570~~466	)
Adjustments to reconcile net loss to net cash used in operating activities:
Change in fair value of derivative liabilities		~~307~~210,~~412~~043			~~184~~307,~~401~~412
Amortization of license and patent		28,174			62,148
Impairment of patent		18,000			-
Amortization of debt discount		119,555			239,186
Impairment of inventory		81,350			-
Loss on settlement of debt		13,200			-
Amortization of license and patent		1,941			28,174
Unrealized (gain) loss on investments in marketable securities		42			148
Amortization of debt discount		52,592			119,555
Management Compensation		208,871			-
Loss on settlement of debt		-			13,200
Unrealized (gain) loss on investments in marketable securities		-			42
Changes in operating assets and liabilities:
Inventory		(625,~~404~~184	)		(46,~~127~~404	)
Security deposit		~~(2,500~~-	)		-(2,500	)
Prepaid expense		(10,000	)		1,000
Prepaid expense and other current assets		57,200			(10,000	)
Accounts payable and accrued liabilities		3944,~~684~~831			~~183~~39,~~752~~684
Due to related party		~~(470~~-	)		~~1,803~~(470	)
Net Cash Used in Operating Activities		(~~223~~249,~~773~~517	)		(~~227~~223,~~259~~773	)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from issuance for common stock		~~178,100~~-			-178,100
Proceed from related party		~~51,044~~-			151,~~623~~044
Repayment to related party		~~(50,000~~-	)		(150,~~623~~000	)
Repayment of notes payable - related party		-			(25,272	)
Proceeds from notes payable		32,096			-
Proceeds from convertible notes		~~80,000~~-			~~195~~80,000
Net Cash Provided by Financing Activities		259,144			169,728
Proceeds from issuance for preferred stock		294,115			-
Net change in cash		35,371			(57,531	)
Net Cash Provided by Financing Activities		326,211			259,144
Cash at beginning of period		25,405			82,936
Net change in cash		76,694			35,371
Cash at end of period	$	60,776		$	25,405
Cash at beginning of period		60,776			25,405
Cash at end of period	$	137,470		$	60,776
SUPPLEMENTAL CASH FLOW INFORMATION:
Cash paid for income taxes	$	-		$	-
Cash paid for interest	$	-		$	~~4,728~~-
NON-CASH INVESTING AND FINANCING ACTIVITIES
Derivative liability recognized as debt discount	$	~~150,000~~-		$	~~217~~150,000
Issuance of common stock for conversion of debt	$	~~282~~202,~~111~~643		$	~~521~~282,~~679~~111
Issuance Series A preferred stock for license fee	$	22,625		$	-
Issuance of Series A preferred stock for license fee	$	1,500		$	22,625
Issuance Series B preferred stock for license fee	$	18,000		$	-
Issuance of Series B preferred stock for license fee	$	3,000		$	18,000
Issuance Series B preferred stock for settlement of debt - related party	$	16,500		$	-
Issuance of Series B preferred stock for settlement of debt - related party	$	1,500		$	16,500
Debts forgiveness - related party	$	-		$	10,000
Issuance of Series C preferred stock for purchase of inventory	$	60,000		$	-
Warrant issued for Patent’s acquisition	$	-		$	5,429
Stock payable for consulting service	$	150,000		$	-
Debt Forgiveness	$	310,245		$

The accompanying notes are an integral part of these consolidated financial statements.

25F-6 Table of Contents

BIOADAPTIVES, INC.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

1. DESCRIPTION OF BUSINESS AND HISTORY

Description of business

BioAdaptives, Inc. (“BioAdaptives” or the “Company”) was incorporated in Delaware on April 19, 2013, under the name Apex 8, Inc. Shortly afterwards, the Company’s control person sold his interest; new owners appointed management and changed its name to BioAdaptives, Inc. BioAdaptives’ core business is to investigate, market and distribute natural plant, ~~algal~~fungi, and ~~mushroom-~~algal based products and medical devices that improve health and wellness for humans and animals, with an emphasis on pain relief, anti-viral function, and anti-aging properties.

The Company’s corporate office is located at 2620 Regatta Drive, Suite 102, Las Vegas, NV 89128.

Reverse stock split

On November 20, 2024, the Company, filed with the Secretary of State of the State of Nevada, a Certificate of Change, pursuant to Nevada Revised Statutes 78.209, to effect a one-for-three hundred (1-for-300) reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding Common Stock, par value $0.001 per share. The Reverse Stock Split was effective as of November 21, 2024. This reverse stock split affected the voting rate and conversion rate of Preferred Stock except for Series C Preferred Stock.

All share and per share information in these financial statements retroactively reflect this reverse stock split.

Stock Dividend

On December 2, 2024, the Company approved the issuance of stock dividends. Each Common Stockholder received one (1) additional share of Common Stock for each share owned. The Company account for this stock dividend as forward stock split

All share and per share information in these financial statements retroactively reflect this stock dividend.

2. SUMMARY OF SIGNIFICANT POLICIES

Basis of Presentation

The Company represents its consolidated financial statements were prepared in accordance with US GAAP and the rules of the Securities and Exchange Commission and that, in the opinion of management, all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of financial position and the results of operations for the interim period presented have been reflected herein. The results of operations are historical and not necessarily indicative of the results to be expected for any future period.

Use of estimates

The preparation of consolidated financial statements in conformity with US GAAP requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses, and related disclosures of contingent assets and liabilities. These estimates and judgments are based on historical information, information that is currently available to the Company, and on various other assumptions that the Company believes to be reasonable under the circumstances. Actual results could differ from those estimates.

Cash and cash equivalents

Cash and cash equivalents consist of cash and short-term investments with original maturities of less than 90 days. Cash equivalents are placed with high -credit -quality financial institutions and are primarily in money market funds. The carrying value of those investments approximates fair value. As of December 31, ~~2023~~2024, and ~~2022~~2023, the Company had $60261,~~776~~885 and $8288,~~936~~ 557 cash equivalents, respectively.

F-7

Table of Contents

Accounts Receivable and Allowance for Uncollectible Accounts

Substantially all of the Company’s accounts receivable balance is related to trade receivables. Trade accounts receivable are recorded at the invoiced amount and do not bear interest. The allowance for doubtful accounts is the Company’s best estimate of the amount of probable credit losses in its existing accounts receivable. The Company reviews its allowance for doubtful accounts daily and past due balances and a specified amount are reviewed individually for collectability. Account balances are charged off after all means of collection have been exhausted and the potential for recovery is considered remote. During the years ended December 31, ~~2023~~2024 and ~~2022~~2023, the Company did not record bad debt expense.

Investment Securities

Equity securities are classified as available for sale. All available for sale securities are classified as current assets as they are available to support the Company’s current operating needs in the next 12 months.

26 Table of Contents

In accordance with Accounting Standards Codification (“ASC”) 320-10, “Investments-Debt and Equity Securities,” the Company evaluates its securities portfolio for other-than-temporary impairment (“OTTI”) throughout the year. Each investment that has a fair value less than the book value is reviewed on a quarterly basis by management. Management considers at a minimum the following factors that, both individually or combination, could indicate that the decline is other-than-temporary: (a) the Company has the intent to sell the security; (b) it is more likely than not that it will be required to sell the security before recovery; and (c) the Company does not expect to recover the entire amortized cost basis of the security. Among the factors that are considered in determining intent is a review of capital adequacy, interest rate risk profile and liquidity at the Company. An impairment charge is recorded against individual securities if the review described above concludes that the decline in value is other-than-temporary.

Inventory

Inventories, consisting of products available for sale, are primarily accounted for using the first-in-first-out (“FIFO”) method and are valued at the lower of cost or market value. Inventories on hand are evaluated on an on-going basis to determine if any items are obsolete or in excess of future market needs. Items determined to be obsolete are reserved for. As of December 31, ~~2023~~2024 and ~~2022~~2023, the Company had finished goods of $19,115 and $15,281, respectively, and determined that no reserve was required.

Intangible assets

Intangible assets with an indefinite life are not amortized and are tested for impairment annually or more frequently if events or changes in circumstances indicate that they might be impaired.

Intangible assets with finite lives are initially recorded at cost and amortized on a straight-line basis over the estimated economic useful lives of the respective assets.

We evaluate the recoverability of intangible assets periodically by taking into account events or circumstances that may warrant revised estimates of useful lives or that indicate the asset may be impaired.

Financial Instruments and Fair Value Measurements

As defined in ASC 820” Fair Value Measurements,” fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. The Company classifies fair value balances based on the observability of those inputs. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement).

27F-8 Table of Contents

The following table summarizes fair value measurements by level as of December 31, ~~2023~~2024 and ~~2022~~2023, measured at fair value on a recurring basis:

	Total Carrying Value		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	as of December 31, 2023		(Level 1)		(Level 2)		(Level 3)
	2024		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	-	$	-	$	-	$	-
Liabilities
Derivative liabilities	$	~~977~~1,~~872~~053,249	$	-	$	-	$	~~977~~1,~~872~~053,249

	Total Carrying Valueas of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	Total Carrying Value as of December 31,		Quoted Market Prices in Active Markets		Significant Other Observable Inputs		Significant Unobservable Inputs
	2022		(Level 1)		(Level 2)		(Level 3)
	2023		(Level 1)		(Level 2)		(Level 3)
Assets:
Equity Securities	$	42-	$	42-	$	-	$	-
Liabilities
Derivative liabilities	$	~~686~~977,~~856~~872	$	-	$	-	$	~~686~~977,~~856~~872

Derivative Financial Instruments

The Company does not use derivative instruments to hedge exposures to cash flow, market or foreign currency risks. We evaluate all of our financial instruments to determine if such instruments are derivatives or contain features that qualify as embedded derivatives. For derivative financial instruments that are accounted for as liabilities, the derivative instrument is initially recorded at its fair value and is then re-valued at each reporting date, with changes in the fair value reported in the statements of operations. For stock-based derivative financial instruments, the Company used a Black Scholes valuation model to value the derivative instruments at inception and on subsequent valuation dates. The classification of derivative instruments, including whether such instruments should be recorded as liabilities or as equity, is evaluated at the end of each reporting period. Derivative liabilities are classified in the balance sheet as current or non-current based on whether or not net-cash settlement or conversion of the instrument could be required within 12 months of the balance sheet date.

Revenue recognition

Revenues are recognized when control of the promised goods or services are transferred to a customer, in an amount that reflects the consideration that the Company expects to receive in exchange for those goods or services. The Company applies the following five steps in order to determine the appropriate amount of revenue to be recognized as it fulfills its obligations under each of its agreements:

	·	identify the contract with a customer;
	·	identify the performance obligations in the contract;
	·	determine the transaction price;
	·	allocate the transaction price to performance obligations in the contract; and
	·	recognize revenue as the performance obligation is satisfied.

28F-9 Table of Contents

Cost of revenue

Cost of revenue includes the inventory purchased from a related party.

Stock-based compensation

The Company accounts for stock-based compensation arrangements with employees, nonemployee directors and consultants using a fair value method, which requires the recognition of compensation expense for costs related to all stock-based payments, including stock options, on a straight-line basis over the requisite service period in the Company’s consolidated statements of operations. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant.

Concentration of credit risk

Financial instruments that potentially expose the Company to significant concentrations of credit risk consist principally of cash. The Company places its cash with financial institutions with high credit ratings.

Income taxes

The Company records income taxes under the asset and liability method, whereby deferred tax assets and liabilities are recognized based on the future tax consequences attributable to temporary differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective tax bases, and attributable to operating loss and tax credit carryforwards. Accounting standards regarding income taxes require a reduction of the carrying amounts of deferred tax assets by a valuation allowance, if based on the available evidence, it is more likely than not that such assets will not be realized. Accordingly, the need to establish valuation allowances for deferred tax assets is assessed at each reporting period based on a more- likely-than-not realization threshold. This assessment considers, among other matters, the nature, frequency and severity of current and cumulative losses, forecasts of future profitability, the duration of statutory carryforward periods, the Company’s experience with operating loss and tax credit carryforwards not expiring unused, and tax planning alternatives.

The Company recorded valuation allowances on the net deferred tax assets. Management will reassess the realization of deferred tax assets based on the accounting standards for income taxes each reporting period. To the extent that the financial results of operations improve, and it becomes more likely than not that the deferred tax assets are realizable, the Company will be able to reduce the valuation allowance.

Significant judgment is required in evaluating the Company’s tax positions and determining its provision for income taxes. During the ordinary course of business, there are many transactions and calculations for which the ultimate tax determination is uncertain. Accounting standards regarding uncertainty in income taxes provides a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates it is more likely than not that the position will be sustained on audit, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount which is more than 50% likely, based solely on the technical merits, of being sustained on examinations. The Company considers many factors when evaluating and estimating its tax positions and tax benefits, which may require periodic adjustments, and which may not accurately anticipate actual outcomes.

Earnings (loss) per share

Basic earnings (loss) per common share is computed by dividing net income (loss) available to common shareholders by the weighted-average number of shares of common stock outstanding during the period. Diluted earnings per common share is computed by dividing income available to common shareholders by the weighted-average number of shares of common stock outstanding during the period increased to include the number of additional shares of common stock that would have been outstanding if potentially dilutive securities had been issued.

29F-10 Table of Contents

For the years ended December 31, ~~2023~~2024 and ~~2022~~2023, the following common stock equivalents were excluded from the computation of diluted net loss per share as the result of the computation was anti-dilutive.

	December 31,		December 31,
	2023		2022
	2024		2023
	(Shares)		(Shares)
Series A Preferred Stock		1455,~~250,000~~833		847,~~000,000~~500
Series B Preferred Stock		2296,~~500,000~~667		-75,000
Convertible notes		2,010,470,120		1,134,061,477
Series C Preferred Stock		100,000,000		-
Total		2,047,220,120		1,142,061,477
Series D Preferred Stock		4,792,339		-
Convertible notes		6,185,001		2,873,921
Total		111,129,840		2,996,421

Lease

The Company leases office space for corporate activities.

In accordance with ASC 842, “Leases,” we determine if an arrangement is a lease at inception.

The office lease meets the definition of a short-term lease because the lease term is 12 months or less. Consequently, consistent with Company’s accounting policy election, the Company does not recognize the right-of-use asset and the lease liability arising from this lease.

Recent Accounting Pronouncements

In June 2022, the FASB issued ASU 2022-03, ASC Subtopic “Fair Value Measurement (Topic 820): Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions”. These amendments clarify that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring fair value. The amendments in this update are effective for public business entities for fiscal years, including interim periods within those fiscal years, beginning after December 15, 2023. Early adoption is permitted. The Company is currently assessing the impact of the adoption of this standard on its consolidated financial statements.

3. GOING CONCERN

The accompanying consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. The Company has incurred losses since inception and had an accumulated deficit of $89,~~264~~163,~~145~~306 as of December 31, ~~2023~~2024. The Company requires capital for its contemplated operational and marketing activities. The Company’s ability to raise additional capital through the future issuances of common stock is unknown. Obtaining additional financing, successful development of the Company’s contemplated plan of operations, and the transition, ultimately, to profitable operations are necessary for the Company to continue operations. The ability to successfully resolve these factors raises substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements of the Company do not include any adjustments that may result from the outcome of these aforementioned uncertainties.

In order to mitigate the risk related with this uncertainty, the Company plans to issue additional shares of common stock for cash and services during the next 12 months.

4.F-11 ~~MARKETABLE~~Table ~~SECURITIES~~of Contents

~~Equity securities as of December 31, 2023 and 2022, were comprised of 105,736 shares of common stock of Hemp, Inc~~4. ~~(HEMP.PK)~~PREPAID ~~recorded at fair value of $0 and $42, respectively.~~EXPENSE

30In ~~Table~~November 2024, the Company entered into a consulting agreement with six months term. The Company shall pay $150,000 as a one-time compensation for consulting services upon execution of ~~Contents~~the agreement. Additionally, the Company will pay consulting fee of $5,000 per month. During the year ended December 31, 2024, the Company recorded consulting expense of $55,000.

As of December 31, 2024 and 2023, the Company recorded prepaid expense of $100,000 and $10,000 as prepaid profession fee, and stock payable of $150,000 for one-time compensation and $0, respectively.

5. ACCOUNTS PAYABLE AND ACCRUED LIABILITIES

Accounts payable and accrued liabilities aa of December 31, ~~2023~~2024 and ~~2022~~2023 consists of the following:

	December 31,		December 31,
	2023		2022
	2024		2023
Accounts payable	$	35,~~283~~999	$	63,~~939~~283
Accrued salary		300,000		300,000
Accrued salary for a former chief financial office		-		300,000
Accrued interest		~~139~~172,~~277~~438		~~101~~139,~~966~~277
Accrued liabilities		1,~~019~~021		1,~~015~~019
	$	~~443~~179,~~579~~458	$	~~409~~443,~~920~~579

6. CONVERTIBLE NOTES

Convertible notes as of December 31, ~~2023~~2024 and ~~2022~~2023 consist of the following:

	December 31,			December 31,
	2023			2022
	2024			2023
Convertible Notes - originated in April 2018	$	95,000		$	95,000
Convertible Notes - originated in June 2018		166,000			166,000
Convertible Notes - originated in October 2018		50,000			50,000
Convertible Notes - issued fiscal year 2022		-			78,440
Convertible Notes - issued fiscal year 2023		-			63,250
Convertible Notes - issued fiscal year 2023		63,250			-
Total convertible notes payable		311,000			374,250
Total convertible notes payable		374,250			389,440
Less: Unamortized debt discount		-			(52,592	)
Less: Unamortized debt discount		(52,592	)		(7,647	)
Total convertible notes		311,000			321,658
Total convertible notes		321,658			381,793
Less: current portion of convertible notes		311,000			321,658
Less: current portion of convertible notes		321,658			381,793
Long-term convertible notes	$	-		$	-

For the years ended December 31, ~~2023~~2024 and ~~2022~~2023, the interest expense on convertible notes was $4338,~~062~~278 and $4943,~~402~~062, respectively. As of December 31, ~~2023~~2024 and ~~2022~~2023, the accrued interest was $~~137~~171,~~955~~507 and $~~100~~137,~~919~~955, respectively.

The Company recognized amortization expense related to the debt discount of $~~119~~52,~~555~~592 and $~~239~~119,~~186~~555 for the years ended December 31, ~~2023~~2024 and ~~2022~~2023, respectively, which is included in interest expense in the statements of operation.

Conversion

During the year ended December 31, ~~2023~~2024, the Company converted notes with principal amounts of $~~109~~63,~~690~~250 and accrued interest of $64,~~026~~726 into ~~443~~2,~~205~~239,~~460~~792 shares of common stock. The corresponding derivative liability at the date of conversion of $~~166~~134,~~396~~666 was credited to additional paid in capital.

~~During~~F-12 ~~the~~Table ~~year ended December 31, 2022, the Company converted notes with principal amounts~~ of $238,510 and accrued interest of $11,582 into 201,734,985 shares of common stock. The corresponding derivative liability at the date of conversion of $271,587 was credited to additional paid in capital.Contents

During the year ended December 31, ~~Table~~2023, the Company converted notes with principal amounts of ~~Contents~~$109,690 and accrued interest of $6,026 into 1,477,352 shares of common stock. The corresponding derivative liability at the date of conversion of $166,396 was credited to additional paid in capital.

Convertible Notes – Issued during the year ended December 31, 2018

During the year ended December 31, 2018, the Company issued a total principal amount of $426,000 in convertible notes for cash proceeds of $426,000. The convertible notes were also provided with a total of ~~107,000~~713 common shares valued at $22,210. The terms of these convertible notes are summarized as follows:

	·	Term two years;

	·	Annual interest rates 12%;

	·	Convertible at the option of the holders at any time

	·	Conversion prices are based on 50% discount to market value for the common stock based on a 4-week weekly average of the closing price.

Convertible Notes - Issued during the year ended December 31, 2021

During the year ended December 31, 2021, the Company issued a total principal amount of $222,500 in convertible note for cash proceeds of $205,000. The terms of convertible note are summarized as follows:

· Term one year; · Annual interest rates 10%; · Convertible at 180 days from issuance · Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

Convertible Notes - Issued during the year ended December 31, 2022

During the year ended December 31, 2022, the Company issued a total principal amount of $211,500 in convertible notes for cash proceeds of $195,000. The terms of convertible notes are summarized as follows:

Convertible Notes - Issued during the year ended December 31, 2023

During the year ended December 31, 2023, the Company issued a total principal amount of $94,500 in convertible notes for cash proceeds of $80,000. The convertible notes were also provided with a total of 1,477,352 common shares valued at $282,111. The terms of convertible notes are summarized as follows:

	·	Term one year;

	·	Annual interest rates 10%;

	·	Convertible at any time

	·	Conversion prices are based on 39% discount to the lowest trading price during the 20-trading day period ending on the latest complete training day prior to the conversion date.

32 Table of Contents

The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the year ended December 31, 2023, amounted to $728,213, and $150,000 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $578,213 was recognized as a “day 1” derivative loss.

The Company valued the conversion feature using the Black-Scholes pricing model. The fair value of the derivative liability for all the notes that became convertible, including the notes issued in prior years, during the year ended December 31, 2022, amounted to $276,414, and $217,000 of the value assigned to the derivative liability was recognized as a debt discount to the notes while the balance of $59,414 was recognized as a “day 1” derivative loss.

7. DERIVATIVE LIABILITIES

The Company analyzed the conversion option for derivative accounting consideration under ASC 815, Derivatives and Hedging, and hedging, and determined that the instrument should be classified as a liability since the conversion option becomes effective at issuance resulting in there being no explicit limit to the number of shares to be delivered upon settlement of the above conversion options. The Company accounts for warrants as a derivative liability due to there being no explicit limit to the number of shares to be delivered upon settlement of all conversion options.

Fair Value Assumptions Used in Accounting for Derivative Liabilities.

ASC 815 requires us to assess the fair market value of derivative liability at the end of each reporting period and recognize any change in the fair market value as other income or expense item.

~~The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the Black~~F-~~Scholes~~13 ~~pricing~~Table ~~model to calculate the fair value as~~ of December 31, 2023. The Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the risk-free interest rate, the current stock price, the estimated volatility of the stock price in the future, and the dividend rate. Changes to these inputs could produce a significantly higher or lower fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.Contents

~~For~~The Company determined our derivative liabilities to be a Level 3 fair value measurement and used the ~~years~~Black-Scholes ~~ended~~pricing model to calculate the fair value as of December 31, ~~2023~~2024. ~~and~~The ~~2022~~Black-Scholes model requires six basic data inputs: the exercise or strike price, time to expiration, the ~~estimated~~risk-free ~~fair~~interest ~~values~~rate, the current stock price, the estimated volatility of the ~~liabilities~~stock ~~measured~~price onin the future, and the dividend rate. Changes to these inputs could produce a ~~recurring~~significantly ~~basis~~higher ~~are~~or aslower ~~follows:~~fair value measurement. The fair value of each convertible note is estimated using the Black-Scholes valuation model.

	Year ended		Year ended
	December 31,		December 31,
	2023		2022
Expected term	0.18- 1.00 years		0.06 - 0.51 years
Expected average volatility	141% - 288%		72% - 164%
Expected dividend yield		-		-
Risk-free interest rate	4.76% - 5.53%		0.17% - 4.72%

For the years ended December 31, 2024 and 2023, the estimated fair values of the liabilities measured on a recurring basis are as follows:

The following table summarizes the changes in the derivative liabilities during the years ended December 31, 2023 and 2022.

	Years ended			Year ended
	December 31,			December 31,
	2024			2023
Expected term	0.22- 0.46 years			0.18- 1.00 years
Expected average volatility	231% - 294		%	141% - 288		%
Expected dividend yield		-			-
Risk-free interest rate	5.25% - 5.48		%	4.76% - 5.53		%

Fair Value Measurements Using Significant Observable Inputs (Level 3)
Balance - December 31, 2021	$	557,042
Addition of new derivatives recognized as debt discounts		217,000
Addition of new derivatives recognized as loss on derivatives		59,414
Settled on issuance of common stock		(271,587	)
(Gain) loss on change in fair value of the derivative		124,987
Balance - December 31, 2022	$	686,856
Addition of new derivatives recognized as debt discounts		150,000
Addition of new derivatives recognized as loss on derivatives		578,213
Settled on issuance of common stock		(166,396	)
(Gain) loss on change in fair value of the derivative		(270,801	)
Balance - December 31, 2023	$	977,872

The following table summarizes the changes in the derivative liabilities during the years ended December 31, 2024 and 2023.

33 Table of Contents

Fair Value Measurements Using Significant Observable Inputs (Level 3)

Balance - December 31, 2022	$	686,856

Addition of new derivatives recognized as debt discounts		150,000
Addition of new derivatives recognized as loss on derivatives		578,213
Settled on issuance of common stock		(166,396	)
(Gain) loss on change in fair value of the derivative		(270,801	)
Balance - December 31, 2023	$	977,872

Settled on issuance of common stock		(134,666	)
(Gain) loss on change in fair value of the derivative		210,043
Balance - December 31, 2024	$	1,053,249

The aggregate (gain) loss on derivatives during the years ended December 31, ~~2023~~2024 and ~~2022~~2023 was as follows.

	Years ended
	December 31,
	2023			2022
	2024			2023
Day one loss due to derivative liabilities on convertible notes	$	~~578,213~~-		$	59578,~~414~~213
(Gain) loss on change in fair value of the derivative liabilities		~~(270~~210,~~801~~043	)		~~124~~(586,~~987~~857	)
	$	~~307~~210,~~412~~043		$	~~184~~(8,~~401~~644	)

F-14

Table of Contents

8. STOCKHOLDERS’ EQUITY

Preferred Stock

On ~~January~~March 2413, ~~2022~~2025, the ~~Board~~increase ofin ~~Directors~~number of ~~the~~preferred ~~Company’s,~~shares ~~approved~~from ~~for~~10,000,000 anto ~~increase~~31,000,000 inhaving the ~~number~~par value of 0.0001 per share was authorized ~~shares~~by written consent of the ~~Company’s~~holders ~~preferred~~of ~~stock~~a ~~from 5,000,000 shares~~majority ~~to 10,000,000 shares~~of our outstanding voting stock.

~~The~~On ~~Company~~January is24, ~~authorized~~2022, tothe ~~issue 10,000,000 shares~~Board of ~~$0.0001 par~~Directors ~~value~~of ~~preferred~~the ~~stock~~Company’s, approved for an increase in the number of ~~which 4,000,000 have~~authorized ~~been~~shares ~~designated~~of asthe ~~Series~~Company’s Apreferred ~~Preferred~~stock ~~Stock~~from 2,500,000 shares ~~and~~to 5,000,000 ~~have been designated as Series B Preferred Stock~~shares.

The Company is authorized to issue 10,000,000 shares of $0.001 par value preferred stock, of which 4,000,000 have been designated as Series A Preferred Stock, 5,000,000 have been designated as Series B Preferred Stock, 1,000,000 have been designated as Series C Preferred Stock and 4,000,000 have been designated as Series D Preferred Stock.

Series A Preferred Stock

On February 6, 2020, the Company established its Series A Preferred Stock, par value $0.001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series A Preferred Stock.

The Company may use the Series A Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series A Preferred Stock have enhanced voting privileges under certain circumstances; the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 5:1 ratio.

During the year ended December 31, ~~2023~~2024, the Company issued 1500,~~250,~~000 shares of Series A Preferred Stock valued at $221,~~625~~500 for license fee.

There are 211,~~850,000~~167 and 12,~~600~~850,000 shares of Series A shares issued as of December 31, ~~2023~~2024 and ~~2022~~2023, respectively.

Series B Preferred Stock

On January 24, 2022, the Company established its Series B Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 5,000,000 shares of Series B Preferred Stock.

The Company may use the Series B Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series B Preferred Stock have enhanced voting privileges (~~100~~10:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 10:1 ratio.

34During ~~Table~~the year ended December 31, 2024, the Company issued 1,667 shares of ~~Contents~~Series B Preferred Stock valued at $3,000 for license fee.

During the year ended December 31, ~~2023~~2024, the Company issued 1,500~~,000~~ shares of Series B Preferred Stock valued at $181,~~000~~500 for ~~license~~settlement ~~fee~~of note payable – related party and interest of $860 and $640, respectively.

~~During~~As ~~the~~of ~~year ended~~ December 31, 2024 and 2023, ~~the Company issued 750~~9,~~000~~667 and 7,500 shares of Series B Preferred Stock ~~valued~~are atissued ~~$16,500 for~~and ~~settlement of note payable – related party of $3~~outstanding,~~300.~~ ~~As a result, the Company recorded a loss on settlement of debt of $13,200~~respectively.

~~As of December 31, 2023 and 2022, 2,250,000 and 0 shares of~~ Series BC Preferred Stock ~~are issued and outstanding, respectively.~~

On January 24, 2022, the Company established its Series C Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 1,000,000 shares of Series C Preferred Stock.

The Company may use the Series C Preferred Stock for purpose of asset acquisition or in satisfaction of recognized debt; they are not otherwise available for sale. The Series C Preferred Stock have enhanced voting privileges (1000:1); the collective right to appoint elect one director, at the Holders’ option; and conversion-to-common rights at a 100:1 ratio.

F-15

Table of Contents

During the year ended December 31, 2024, the Company issued 1,000,000 shares of Series C Preferred Stock valued at $60,000 for purchase of inventory.

As of December 31, 2024 and December 31, 2023, 1,000,000 shares and 0 shares of Series C Preferred Stock are issued and outstanding, respectively.

Series D Preferred Stock

On July 4, 2024, the Company established its Series D Preferred Stock, par value $0.0001, by filing a Certificate of Designation with the Delaware Secretary of State. The Company’s board exercised “blank check” authority to establish classes of preferred stock without approval by shareholders under provision of its original Articles of Incorporation and has designated 4,000,000 shares of Series D Preferred Stock.

The may convert the Series D Preferred Stock to Common Stock at a rate of 100 shares of common stock for each share of Series D Preferred Stock. Each Series D Preferred Stock carries the voting rights equal to 100 shares of Common Stock.

During the year ended December 31, 2024, the Company issued 16,667 shares of Series D Preferred Stock for cash valued at $100,000 to Gimhana Dissanayake and John Keener.

During the year ended December 31, 2024, the Company issued 33,333 shares of Series D Preferred Stock for cash valued at $200,000 to Mary Wilkins. The Company received $194,115, $19,115 of which is related to inventory purchased from a vendor paid on behalf of the Company. The remaining $5,885 is classified as subscription receivable as of December 31, 2024.

During the year ended December 31, 2024, the Company issued 22,687 shares of Series D Preferred Stock for compensation of James Keener and Gimhana Dissanayake valued at $208,871.

As of December 31, 2024 and 2023, 72,687 and 0 shares of Series D Preferred Stock are issued and outstanding, respectively.

Common Stock

On January 24, 2022, the holder of a majority of the Company’s outstanding voting stock, approved for an increase in the number of authorized shares of the Company’s common stock from 200,000,000 shares to 750,000,000 shares.

On March 7, 2023, the Company amended its articles of incorporation to increase its authorized common shares from 750,000,000 to 1,250,000,000; this increase will be effective March 27, 2023.

As of December 31, ~~2023~~2024 and ~~2022~~2023, there were ~~895~~4,~~760~~107,~~225~~680 and ~~252~~5,~~544~~971,~~765~~728 shares of the Company’s common stock issued and outstanding, respectively. In addition, as of December 31, ~~2023~~2024 and ~~2022~~2023, there were ~~10,000~~ 66 shares of the Company’s common stock issuable.

Fiscal year 2024

During the year ended December 31, 2024, the Company issued Common shares as follows;

	·	2,239,794 shares of common stock valued at $202,643 for conversion of debt.
	·	Reverse stock split adjustment of 3,904.

Fiscal year 2023

During the year ended December 31, 2023, the Company issued Common shares as follows;

	·	~~443~~2,~~205~~954,~~460~~696 shares of common stock valued at $282,112 for conversion of debt.
	·	~~200~~1,~~000~~333,~~000~~328 shares of common stock at $0.001 per share, net of offering cost of $21,900.

~~Fiscal~~F-16 ~~year~~Table ~~2022~~of Contents

During the year ended December 31, 2022, the Company issued 201,734,985 shares of common stock valued at $521,679 for conversion of debt.

Warrant

On February 6, 2022, in conjunction with purchase of patent, the Company granted 1,000,000 shares for period of two years with exercise price of $0.006 per share. The fair value of granted shares at the issuance date was $5,429. The Company recorded warrant as additional paid-in-capital.

The estimated fair values of the warrant are as follows:

	Year Ended
	December 31, 2022
Expected term	2.00 years
Expected average volatility		235	%
Expected dividend yield		-
Risk-free interest rate		1.31	%

35 Table of Contents

9. RELATED PARTY TRANSACTIONS

Notes payable – related party

During the year ended December 31, ~~2023~~2024 and ~~2022~~2023, the Company repaid notes payable to a related party of $0860 and $~~25,272~~0 and recognized interest of $~~273~~177 and $~~533~~273, respectively.

AsDuring ofthe year ended December 31,. ~~2023 and 2022~~2024, ~~the Company recorded~~ notes payable -to a related party of $~~5,144~~4283 and ~~$8,444 and~~ accrued interest of $~~1,320~~856 ~~and~~were ~~$1,047, respectively~~forgiven. ~~The note is a 4% interest bearing promissory note that the term is 1 year.~~

As of December 31, 2024 and 2023, the Company recorded notes payable - related party of $4,283 and $5,144 and accrued interest of $856 and $1,320, respectively. The note is a 4% interest bearing promissory note that the term is 1 year.

Due to related party

During the year ended December 31, 2024, accounts payable of $2,729 was paid by a related party and due to related party of $5106 was forgiven

As of December 31, 2024, and 2023, the Company owed Dr. Edward E. Jacobs, M.D.,$0.0 and $2,377 respectively

Employee agreements

~~Year~~In May 2024, the Company entered into an employment agreement as our chief executive officer. The Company agrees to pay a salary of $300,000 per annum. During the year ended December ~~2022~~31, 2024, the Company recorded payroll expense of $158,871 and the Company issued 18,062 shares of Series D Preferred Stock for payroll.

OnIn ~~January~~May 12024, ~~2022,~~ the Company entered into aan ~~Restricted Stock Unit Termination Agreement for modification of~~ employment ~~agreements~~agreement ~~signed~~as ~~during~~our ~~2021~~director with ~~Dr.~~a ~~Edward~~one-year Eterm. ~~Jacobs, M.D, Charles Townsend and Robert Ellis.~~ The ~~employees~~Company ~~agreed~~agrees to ~~waive~~pay ~~all~~a ~~rights~~salary ~~under previously issued RSUs as~~ of ~~January 1~~$5, ~~2022, in exchange for one -time issuance 100,~~000 ~~shares~~ ofper ~~restricted common stock~~month. During ~~In addition,~~ the ~~Employment~~year ~~Agreement~~ended ~~was~~December ~~modified~~31, to2024, ~~provide for compensation in~~ the ~~form~~Company ofrecorded apayroll ~~number~~expense of ~~Warrants~~$50,000 ~~equivalent~~and ~~to twice (2X)~~ the ~~number~~Company ofissued 4,625 shares ~~previously payable in RSUs and the exercise price~~ of ~~the~~Series ~~Warrant~~D ~~shall~~Preferred beStock ~~the~~for ~~OTC Market price of the Company’s common shares~~payroll.

During the year ended December 31, 2022, the Company accrued salary of $133,334. As of December 31, 2023 and 2022, the Company owes a salary of $300,000.

Debt forgiveness

During the year ended December 31, 2022, the Company recognized $10,000 accrued salary payable to Robert Ellis related to year 2020 as additional paid-in -capital, based on released agreement in year 2020 due to COVID-19-based financial and other considerations.

License and patent

As of December 31, ~~2023~~2024 and ~~2022~~2023, License and patent consist of the following:

	December 31,			December 31,
	2023			2022
	2024			2023
License	$	2024,~~000~~500		$	-20,000
Patent		~~5,429~~-			5,429
		25,429			5,429
		24,500			25,429
Accumulated amortization		(924,~~988~~500	)		(29,~~439~~988	)
	$	~~15,441~~-		$	215,~~990~~441

The term of licenses is a range from 1 to 3 years for certain products. The Company agrees to pay a royalty on sales of the Products during the term of licensee’s equivalent to 2 – 5% of gross product sales amounts (“GPSA”). Such royalty shall be payable only after the Licensor attains a GPSA of $20,000 to $30,000 in any calendar month and shall be payable on the entire GPSA for such period.

For the year ended December 31, ~~2023~~2024 and ~~2022~~2023, the Company recorded amortization expense of $1,941 and $28,174 and impairment loss $6218,~~148~~000 and $0, respectively.

36F-17 Table of Contents

The following table outlines the estimated future amortization expense related to intangible assets held as of December 31, 2023:

2024	$	6,166
2025		6,000
2026		3,000
Thereafter		-
	$	15,166

10. PROVISION FOR INCOME TAXES

The Company provides for income taxes under ASC 740,” Income Taxes.” Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax basis of assets and liabilities and the tax rates in effect when these differences are expected to reverse. A valuation ~~allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.~~

allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations.

The provision for income taxes differs from the amounts which would be provided by applying the statutory federal income tax rate of 21% to the net loss before provision for income taxes for the following reasons:

	December 31,			December 31,
	2023			2022
	2024			2023
Net operating loss	$	(59133,~~955~~670	)	$	(9959,~~116~~955	)
Valuation allowance		59133,~~955~~670			9959,~~116~~955
Income tax expense per books	$	-		$	-

The cumulative tax effect at the expected rate of 21% of significant items comprising our net deferred tax amount is as follows:

	December 31,			December 31,
	2023			2022
	2024			2023
NOL Carryover	$	~~585~~718,~~167~~837		$	~~525~~585,~~212~~167
Valuation allowance		(~~585~~718,~~167~~837	)		(~~525~~585,~~212~~167	)
Net deferred tax asset	$	-		$	-

Due to the change in ownership provisions of the Income Tax laws of the United States of America, net operating loss carry forwards of approximately $23,~~787~~423,000 for federal income tax reporting purposes are subject to annual limitations. When a change in ownership occurs, net operating loss carry forwards may be limited as to use in future years.

11. COMMITMENTS AND CONTINGENCIES

Short -term Leases

The Company has not entered into any long-term leases, contracts, or commitments. In November, 2023, the Company ~~leasd~~leased an office ~~which~~for ~~the~~a ~~term is~~ month -to -month term. ~~For~~As ~~the~~of ~~years ended~~ December 31, ~~2023~~2024, the Company incurred rent expense of $42,~~510~~132. The Company recorded a security deposit of $2,500 as of December 31, 2024, and 2023.

12. SUBSEQUENT EVENTS

On ~~October~~January 1131, ~~2023~~2025, the Company ~~filed~~issued ~~a new Reg A for the marketing of 250~~500,000~~,000~~ ~~common~~warrants ~~shares~~to atMark Frissora, a ~~price~~member ~~range~~ of ~~$0.001 to $0.003, to be determined after qualifying. This new Reg A is to provide additional funding for~~ the ~~marketing~~Board ~~for~~of ~~BioAdaptives itself~~Directors, ~~and~~to ~~also~~purchase ~~for its wholly owned subsidiary~~500,000 ~~LiveStock~~shares ~~Impact~~of ~~Inc,~~common ~~The~~stock ~~Company~~at isan ~~looking~~exercise toprice ~~expand its range~~ of ~~targeted~~$10.00 ~~human~~per ~~health supplements~~share. ItThe iswarrants ~~also~~become ~~focused~~exercisable on ~~the~~January ~~marketing~~31, ~~effort of LiveStock Impact~~2028, ~~Inc~~ and ~~its~~expire ~~wholesale activities as well as its interest in botanical drugs. Towards this end, since October, the Company has been working with a professional entity~~ on ~~its press releases and marketing promotions. It expects to intensify its marketing outreach in the next two quarters. In~~ January ~~2024~~31, ~~the Company launches an innovative food Lab for the development of treats and supplement powder for human~~2035, ~~equine~~if ~~and~~not ~~canine~~exercised. The ~~initial~~issuance ~~trials~~was ~~were~~made ~~conducted~~as inpart an established kitchen facility. In January 2024, BioAdaptives signed a Distributor’s agreement with PIXELCANDO SL to distribute FitYourOutfit® (FYO) product in North America. This is a low-cost AI smart phone app body composition tracking system to detect unwanted muscle mass loss reported with obesity management and also fat loss. In conjunction with its BodyShape Lab division and the AI FYO system product, the Company acquired the distribution rights of an ~~All-In-One~~equity ~~dietary~~incentive ~~supplement formula,, NaturaComplete™~~plan.~~This~~ ~~new~~The ~~formula~~fair ~~provides~~value ~~a comprehensive array~~ of ~~over~~the 70warrants ~~vitamins, mineral, amino and fatty acids, trace minerals and other nutrients to support general health and obesity management activities. It is expected that NaturaComplete™~~ will be ~~marketed~~recognized ~~within~~as ~~the~~stock-based ~~first~~compensation 2expense ~~quarters~~over ~~of 2024 together with Pluripain PMS™, which is designed to help manage~~ the ~~symptoms~~vesting ~~associated~~period ~~with the menstrual cycle and VeganHepplus™, a liver support supplement. Two equine products: Equine All-In-On Extreme and Equine All-In-One Extreme Booster will both be actively launched~~ in ~~the~~accordance ~~first~~with ~~two~~ASC ~~quarters of 2024 for competition and performance horses~~718.

37On ~~Table~~January of23, ~~Contents~~2025, the dividend shares were issued to all common stockholders.

F-18

Table of Contents

PART III

Item 10 Directors, Executive Officers and Corporate Governance

The following information sets forth the names, ages, and positions of our current directors and executive officers as of December 31, ~~2023~~2024 and January 2025.

Name	Age	Principal Positions with Us
Edward E. Jacobs, Jr MD	83	Director & Chief Executive Officer
James E. Keener	54	Chairman & Chief Executive Officer
Robert W. Ellis	82	President and Chief Financial Officer
Gimhana Dissanayake	52	Director
Charles Townsend	77	Chief Operating Officer
Mark Frissora	59	Director (as of January 31 2025)

~~Biographical~~James ~~Information~~E ~~for~~Keener, ~~Edward~~Age E54. ~~Jacobs,~~Chairman Jrand MDChief Executive Officer

~~Edward~~James E.Keener, ~~Jacobs~~CEO of BioAdaptives, JrInc., ~~Age~~is 83a highly accomplished executive with a diverse and impressive career spanning multiple industries. ~~Director~~He has been leading strategic growth initiatives since his appointment in May 2024. His leadership at BioAdaptives emphasizes leveraging the company’s strengths in research-driven nutritional products to enhance health and ~~Chief~~wellness, ~~Executive~~focusing ~~Officer~~on expanding market presence and driving innovation.

~~Dr.~~Before ~~Edward~~his E.role ~~Jacobs,~~at ~~Jr.~~BioAdaptives, aKeener ~~graduate~~was ofthe ~~Princeton~~CEO ~~University~~of ~~and~~a ~~Harvard~~private ~~Medical~~investment ~~school,~~company. isHe managed a ~~biotechnology~~wide ~~consultant~~range ~~with~~of ~~over~~businesses, 25such ~~years’~~as ~~experience~~retail inlocations, ~~biopharmaceutical~~hotels and ~~medical~~hospitality, ~~device development~~agriculture, asand ~~well~~forestry asoperations, 35with ~~years~~domestic ~~of teaching~~ and ~~direct~~international ~~patient care~~reach. ~~Dr.~~This ~~Jacobs~~role ~~has~~showcased ~~participated~~his inability ~~drug~~to ~~development~~handle ~~process from discovery through animal and human studies~~complex, ~~including~~multifaceted ~~regulatory~~asset ~~support~~management ~~for FDA~~ and ~~international~~deliver ~~regulatory~~results ~~affairs,~~across ~~strategic~~diverse ~~planning, and investor relations~~sectors.

~~Dr.~~Earlier ~~Jacobs~~in ~~has~~his ~~extensive clinical operations experience~~career, ~~having~~Keener ~~conducted,~~established himself as ~~chief~~a ~~clinical~~renowned ~~investigator,~~turnaround ~~more~~specialist ~~than~~in 15the ~~human~~air ~~trials~~freight inindustry. ~~the~~As ~~US,~~a ~~Europe,~~performance ~~Eastern Europe~~specialist, ~~and~~he ~~the~~focused ~~Republic~~on ofrevitalizing ~~South~~underperforming ~~Africa.~~contracts Heacross ~~has~~the ~~also~~United ~~served~~States, asdemonstrating ahis ~~medical~~strategic ~~monitor~~thinking and ~~liaison~~ability ~~for~~to ~~clinical~~optimize ~~investigators~~business ~~involved~~operations ~~with~~in ~~international~~high-pressure ~~trials with responsibility for regulatory compliance~~environments.

~~After completing surgical training at Harvard and research positions at the National Heart, Lung and Blood Institute, Bethesda, Maryland, and at Saint Thomas~~Keener’s ~~Hospital~~professional ~~Medical~~journey ~~School,~~began ~~London,~~with ~~Dr. Jacobs was~~ a ~~member~~foundation of ~~the~~public ~~Harvard~~service ~~Medical~~as ~~School~~a ~~staff,~~firefighter ~~combining~~in ~~teaching~~Stockton, ~~with clinical practice and research~~California. HeThis ~~has~~early ~~also~~role ~~served~~reflects onhis ~~the~~commitment ~~Scientific~~to ~~Advisory~~community ~~Board of the Armenise-Harvard Foundation~~ and ~~the~~leadership ~~Publications~~under ~~Committee~~challenging ~~for the New England Journal of Medicine Scientifically~~conditions, ~~Dr.~~qualities ~~Jacobs~~that ~~has~~have ~~made~~carried ~~original~~through ~~observations~~his insubsequent ~~the~~career ~~field of tissue oxygenation therapy and water modification~~achievements. ~~His current focus is on natural products for animal and human use, anti-ageing strategies, and primitive cell biology.~~

HeWith isa anproven ~~author~~track record as a marketer, innovator, and turnaround expert, James Keener brings a wealth of ~~more~~experience ~~than~~to 40every ~~scientific~~endeavor. ~~publications~~He blends operational transformation skills with a strategic focus on growth and isprofitability. ~~the~~His ~~holder~~career trajectory—from firefighter to CEO of ~~four~~a ~~patents~~publicly traded company—illustrates his remarkable ability to adapt, lead, and succeed across varied industries.

~~Biographical~~Gimhana ~~Information~~Dissanayake, ~~for~~Age ~~Robert~~52, ~~W. Ellis~~Director

~~Robert~~Gimhana ~~W Ellis~~Dissanayake, currently ~~Age~~serves ~~82,~~as the Vice President of Operations and ~~Chief~~Sales ~~Financial~~for ~~Officer~~North America at The Hertz Corporation (NYSE: HTZ), bringing over two decades of comprehensive experience and a proven track record of strategic growth and operational excellence to BioAdaptives.

~~Mr.~~With ~~Ellis~~an ~~brings~~illustrious ~~more~~career ~~than~~that ~~forty~~spanned ~~years~~various ofleadership ~~business~~roles ~~management~~at ~~experience~~Hertz, toGimhana ~~the~~is ~~Company~~renowned for his strategic vision and leadership acumen. He has ~~worked~~been ~~extensively~~instrumental in ~~senior~~advancing ~~positions~~the ~~across~~Hertz, aDollar, ~~variety~~and ofThrifty ~~industry disciplines~~brands, ~~including~~significantly ~~aerospace,~~enhancing ~~electronics,~~their ~~communications,~~market presence and ~~international~~competitive ~~marketing~~edge. ~~Mr.~~As ~~Ellis~~the ~~has~~Senior ~~been~~Director anof ~~executive~~Strategic ~~officer~~Partnerships, inhe ~~private~~spearheaded initiatives that fostered key alliances and ~~public~~drove ~~companies,~~substantial ~~both~~growth ~~major~~across ~~entities,~~10 ~~start-ups,~~revenue ~~and~~verticals ~~emerging~~in ~~entities~~North America. HeHis ~~has~~efforts anearned ~~Accounting~~him ~~Degree~~the ~~from~~nickname’ ~~the~~Founder ~~University~~of Canada’ within Hertz, a testament to his successful expansion of ~~Illinois~~the ~~and~~company’s market share in the region. His strategic prowess is a ~~CPA~~valuable asset that will undoubtedly benefit BioAdaptives.

3817 Table of Contents

~~Biographical~~Gimhana’s ~~Information~~educational ~~for~~background ~~Charles~~and ~~Townsend~~extensive professional experience make him an invaluable addition to the BioAdaptives board. He holds an undergraduate degree from Oklahoma State University and an MBA from California State University - Sacramento. In addition, he has completed advanced executive education at Cornell University and the Wharton School of Business.

~~Charles~~Mark ~~Townsend~~P. Frissora, Age 7659, ~~Chief Operating Officer~~ Director

~~Mr.~~Mark ~~Townsend~~Frissora, ~~75,~~most ~~has~~recently ~~a Bachelor of Arts degree in accounting from~~ the ~~University~~CEO ~~of Texas~~ and aPresident ~~Master~~ of ~~Business~~Caesars ~~Administration~~Entertainment, ~~from~~has ~~the~~42 ~~University~~years of ~~North~~business ~~Texas.~~experience Heacross ~~previously~~managerial ~~served~~and infunctional ~~the U~~roles.S. ~~Navy~~He ~~Submarine~~joined ~~Force.~~Caesars ~~Mr.~~in ~~Townsend~~2015 ~~was~~and apreviously ~~cost~~served ~~accounting~~as ~~manager,~~Chairman ~~comptroller,~~ and ~~Chief~~CEO ~~Financial~~of ~~Officer~~Hertz ~~for~~Global ~~several~~Holdings ~~private~~ and ~~public companies~~Tenneco, ~~including NYSE and OTC companies but in the past ten years has not been an officer or director of any publicly traded company~~Inc. ~~Mr. Townsend’s consulting work has emphasized enterprise marketing programs~~, ~~predominantly~~leading inboth ~~the~~Fortune ~~telecommunications~~500 ~~and~~companies ~~home~~through ~~security~~transformative ~~industries~~growth. ~~He most recently was employed by the US Department of Commerce as a District Census Manager for the 2020 US Census.~~

Frissora has a 20-year track record of creating stakeholder value at highly leveraged companies in private equity and public markets, meeting or exceeding expectations in over 92% of 65 quarters during two significant recessions. He led two companies through successful IPOs and guided Caesars out of bankruptcy to its NASDAQ relisting in 2017. At Tenneco, where he served as Chairman and CEO from 1999 to 2006, shareholder value tripled, revenue rose 39%, and the company earned top industry awards for shareholder returns.

During his tenure at Hertz from 2006 to 2014, shareholders saw a 3.6x return post-IPO, with a special dividend paid after the launch. At Caesars, he drove initiatives that increased EBITDA by $812M (55%) and margins by 930 bps, creating $12.5B in value during its bankruptcy turnaround. Frissora currently chairs Arencibia, an advanced engineering company, and co-founded Goodwrx, a gig economy technology solution. He previously served on the boards of Caesars Entertainment, Aptiv, Walgreens Boots Alliance, FMC Corporation, and NCR Corporation, holding key leadership roles on governance, compensation, and finance committees. Mark holds a B.A. from The Ohio State University and has completed executive programs at Babson College and Thunderbird School of Global Management.

Advisory Board

The Company uses an Advisory Board to assist the officers and directors with regard to specific scientific and administrative matters. These advisors did not meet during the period ended December 31, ~~2023~~2020, and we did not call on them due to a lack of need.

Name	Age	Principal Positions with Us
Dr. Jun Gu M.D., Ph.D.	58	Medical Advisor
Reed Harris	68	Advisor
Dr. Antonina Nabokova M.D.	60	Medical Advisor

~~Dr.~~Reed ~~Jun~~Harris, Guthe ~~has~~Senior ~~extensive~~Vice ~~experience~~President inof ~~laboratory~~Athlete ~~toxicology~~Development ~~work~~ and isMarketing ~~frequently~~at ~~called~~the ~~upon~~Ultimate asFighting anChampionship ~~expert~~(UFC) in ~~toxicology~~Las ~~and~~Vegas, ~~pharmacology.~~has Hea ~~received~~distinguished ~~his~~career ~~medical~~spanning ~~degree~~over (M40 years.~~D.)~~ inHe ~~1986~~blends ~~from~~expertise ~~the~~in ~~Second~~martial ~~Military~~arts, ~~Medicine~~business ~~University in Shanghai~~development, ~~China,~~ and acharity Phwork.D. inHis ~~pharmacology~~life ~~from~~and ~~Shanghai~~career ~~Medical~~reflect ~~College~~a atdedication ~~Fudan~~to ~~University~~discipline, ~~in Shanghai~~growth, ~~China~~and ingiving ~~1993~~back to the community.

~~Dr.~~18 ~~Antonina~~Table ~~Nabokova M.D has over 11 years’ experience in clinical trials and managing development~~ of clinical operations in areas such as psychiatry, orphan indication, and urology. Dr. Nabokova currently maintains an office as the head of Representative office of SynteractHCR Deutschland GmbH, in Moscow, Russia. She holds an M.D. from Leningrad Medical University and also obtained a certificate in cardiology from Leningrad Medical University.Contents

Harris works closely with BioAdaptives to introduce new products geared to repair and recover both body and mind after extreme workouts. Reed’s exceptional leadership, business acumen, and dedication to athlete development and community service align perfectly with our mission to deliver innovative health and wellness solutions. His deep experience building and managing successful organizations and his passion for helping others makes him an invaluable asset to BioAdaptives as we expand our reach and impact.

Term of Office

Our Directors are appointed for a one-year term but will hold office until the next annual general meeting of our shareholders or until removed from office inby ~~accordance with~~ our bylaws. Our ~~officers~~board ~~are~~of ~~appointed~~directors byappoints our ~~board~~officers ~~of directors~~ and ~~hold~~holds office until removed by the board.

Family Relationships

None.

Involvement in Certain Legal Proceedings

To the best of our knowledge, during the past ten years, none of the following occurred with respect to a present or former director, executive officer, or employee: (1) any bankruptcy petition filed by or against any business of which such person was a general partner or executive officer either at the time of the bankruptcy or within two years prior to that time; (2) any conviction in a criminal proceeding or being subject to a pending criminal proceeding (excluding traffic violations and other minor offenses); (3) being subject to any order, judgment or decree, not subsequently reversed, suspended vacated, of any court of competent jurisdiction, permanently or temporarily enjoining, barring, suspending or otherwise limiting his or her involvement in any type of business, securities or banking activities; and (4) being found by a court of competent jurisdiction (in a civil action), the SEC or the Commodities Futures Trading Commission to have violated a federal or state securities or commodities law, and the judgment has not been reversed, suspended or vacated.

Committees of the Board

Our company currently does not have nominating, compensation or audit committees or committees performing neither similar functions nor does our company have a written nominating, compensation, or audit committee charter. Our directors believe that it is not necessary to have such committees, at this time, because the board of directors can adequately perform the functions of such committees. Our Common Stock trades on the OTC Bulletin Board, which does not impose standards relating to director independence or the makeup of committees with independent directors, or provide definitions of independence

39 Table of Contents

Our company does not have any defined policy or procedural requirements for shareholders to submit recommendations or nominations for directors. The board of directors believes that, given the stage of our development, a specific nominating policy would be premature and of little assistance until our business operations develop to a more advanced level. Our company does not currently have any specific or minimum criteria for the election of nominees to the board of directors and we do not have any specific process or procedure for evaluating such nominees. The board of directors will assess all candidates, whether submitted by management or shareholders, and make recommendations for election or appointment.

A shareholder who wishes to communicate with our board of directors may do so by directing a written request addressed to our President, Robert W. Ellis, at the address appearing on the first page of this annual report.

Table of Contents

Financial Expert

The Company does not ~~currently~~ have a designated “financial expert” on the Board of Directors. We believe that the cost of obtaining and retaining an independent director who can also serve as our financial expert is prohibitive ~~at this time~~.

Information Concerning Non-Director Executive Officers

~~Neither Dr. Jacobs,~~ Mr. ~~Ellis~~James ~~nor~~E ~~Mr.~~Keener ~~Townsend are currently officers or directors of other publicly held companies. Each of them~~ has an employment ~~contracts~~contract with the Company, under which ~~they~~he ~~are~~is compensated with ~~Restricted~~cash ~~Stock~~or ~~Units,~~stock ~~which~~as ~~they~~he ~~each waived for the year ended December 31, 2023~~elects. ~~Our activities were limited during this period, but we believe all three directors devote sufficient time to the Company’s business and look forward to their service during the current period.~~

Code of Ethics

As of December 31, ~~2023~~2024, we had not adopted a Code of Ethics for Financial Executives, which would include our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions. Potential Conflict of Interest

Potential Conflict of Interest

Since we do not have an audit or compensation committee comprised of independent directors, the functions that would have been performed by such committees are performed by our Board of Directors. Thus, there is a potential conflict of interest in that our directors have the authority to determine issues concerning management compensation, including their own, and audit issues that may affect management decisions. We are not aware of any other conflicts of interest with any of our officers or directors.

Board’s Role in Risk Oversight

The Board of Directors assesses on an ongoing basis the risks faced by BioAdaptives. These risks include financial, technological, competitive, and operational risks. The Board dedicates time at each of its meetings to review and consider the relevant risks faced at that time. In addition, since the Company does not have an Audit Committee, the Board of Directors is also responsible for the assessment and oversight of our financial risk exposures.

Compliance With Section 16(a) of the Exchange Act

Section 16(a) of the Exchange Act requires the Company’s directors, executive officers and persons who own more than ten percent of a registered class of the Company’s equity securities (“10% holders”), to file with the Securities and Exchange Commission (SEC) initial reports of ownership and reports of changes in ownership of Common stock and other equity securities of the Company.

Directors, officers and 10% holders are required by SEC Regulation to furnish the Company with copies of all of the Section 16(a) reports they file. Based solely on a review of reports furnished to the Company and/or written representations from the Company’s directors and executive officers during the fiscal year ended December 31, 2020, there was no compliance with the Section 16(a) filing requirements applicable to its directors, officers and 10% holders for such year.

40 Table of Contents

Involvement on Certain Material Legal Proceedings During the Past Five (5) Years

	(1)	No director, officer, significant employee or consultant has been convicted in a criminal proceeding, exclusive of traffic violations or is subject to any pending criminal proceeding.
	(2)	No bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee or consultant of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general partners or executive officers.
	(3)	No director, officer, significant employee or consultant has been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities or banking activities.
	(4)	No director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

(1) No director, officer, significant employee or consultant has been convicted in a criminal proceeding, exclusive of traffic violations or is subject to any pending criminal proceeding.

(2) No bankruptcy petitions have been filed by or against any business or property of any director, officer, significant employee or consultant of the Company nor has any bankruptcy petition been filed against a partnership or business association where these persons were general partners or executive officers.

(3) No director, officer, significant employee or consultant has been permanently or temporarily enjoined, barred, suspended or otherwise limited from involvement in any type of business, securities or banking activities.

(4) No director, officer or significant employee has been convicted of violating a federal or state securities or commodities law.

Table of Contents

Item 11. Executive Compensation

We have employment agreements with our Chief Executive Officer, ~~President~~who ~~and Chief Financial Officer, each of whom~~ was to be compensated by ~~stock~~cash ~~grants accrued monthly based on current share prices~~ or ~~block~~stock grants ~~during the period ended December 31, 2023~~. ~~In consideration of the Company’s financial performance and lack of liquidity during this period, each of our officers waived compensation and we adjusted compensation accordingly.~~

The Company has no other executive compensation issues which would require the inclusion of other mandated table disclosures.

Director Compensation

Our directors’ compensation is wholly derived from their ~~employment~~Director’s agreement as set out above.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters

The following table sets forth certain information as of December 31, ~~2023~~2024, regarding the number of shares of Common Stock beneficially owned by (i) each person or entity known to us to own more than five percent of our Common Stock; (ii) each of our Named Executive Officers; (iii) each of our directors; and (iv) all of our executive officers and directors as a group. The percentages are based on ~~895,750,225~~ total outstanding Shares as of December 31, ~~2023~~2024.

Except as otherwise noted, the persons named in the table have sole voting and dispositive power with respect to all shares beneficially owned, subject to community property laws where applicable.

As of December 31, ~~2021~~2024

Title of class	Name of beneficial owner	Amount of beneficial ownership		Percent of class		~~Percent of class~~
Common Stock	Edward E. Jacobs, Jr		2,239,531				0.0025	%
Series C	James E Keener	1,000,000 shares			100	%
	Director & Chief Executive Officer
Series D	James E Keener	18,062 shares			24.8	%
	Chairman & Chief Executive Officer
Series D	Gimhana Dissanayake	12,958 shares			17.8	%
	Director

All ~~officers~~Officers and Directors as a Group (32 ~~person~~persons)

(1)	The terms of our convertible notes with PowerUp Lending Group, Ltd. limit its ownership to less than 4.99% of the Company’s outstanding shares at any given time and it does not otherwise report ownership.
(3)	Dr. Jacobs is the sole management of BioScience Associates, Ltd which is the holder of 850,000 shares of the Company’s Series A Preferred Stock and 750,000 shares of the Company’s Series B Preferred Stock. These shares provide him with 100:1 voting rights in certain instances, along with 5:1 conversion rights for Series A Preferred shares and 10:1 conversion right for Series B shares.

Changes in Control

~~Changes~~On inJune ~~Control~~21, 2013, the Company’s sole officer, director and shareholder, Richard Chiang, sold 10,000,000 shares of the Company’s common stock, constituting 100% of its issued and outstanding shares, to Ferris Holding Inc., a Nevada corporation (“FHI”) for a purchase price of $40,000. Effective the same date, Mr. Chiang or the Company appointed Barry K. Epling, who was the sole shareholder of FHI, as Chairman of the Board of Directors, and Gerald A. Epling as its President, Chief Executive Officer, Secretary, Chief Financial Officer and a director; Mr. Chiang then resigned. On September 25, 2013, the Company changed its name to BioAdaptives, Inc.

On ~~June~~October 212, ~~2013~~2017, the ~~Company’s~~Board ~~sole~~of ~~officer,~~Directors ~~director~~appointed Kim Southworth and ~~shareholder,~~Dr. ~~Richard~~Edward ~~Chiang~~E Jacobs, ~~sold~~Jr 10MD as directors and Barry K. Epling resigned as Chairman. FHI donated 9,~~000,000~~628.568 shares of the Company’s common stock, ~~constituting~~to ~~100%~~the Breath of ~~its~~Life ~~issued and outstanding shares~~Foundation, ~~to Ferris Holding Inc.,~~ a ~~Nevada~~Section ~~corporation~~ 501(~~“FHI”~~c)(3) ~~for~~non-profit aorganization. ~~purchase~~At ~~price~~that ~~of $40~~time,~~000.~~ ~~Effective~~these ~~the~~shares ~~same~~constituted ~~date, Mr~~51.84% ~~Chiang~~of or the Company’s ~~appointed~~issued ~~Barry~~and K.outstanding ~~Epling~~shares and, ~~who~~as ~~was~~part of the ~~sole~~grant, ~~shareholder~~Breath of ~~FHI,~~Life asgranted ~~Chairman of~~ the Company’s Board of Directors, ~~and~~an ~~Gerald~~irrevocable A.proxy ~~Epling~~to asvote ~~its~~them. With ~~President,~~these ~~Chief Executive Officer~~actions, ~~Secretary,~~Barry ~~Chief Financial Officer and a director; Mr~~K. ~~Chiang~~Epling ~~then~~terminated ~~resigned.~~his Onrelationship ~~September~~with ~~25, 2013,~~ the Company ~~changed~~as ~~its~~an ~~name~~owner to(direct ~~BioAdaptives~~or indirect), ~~Inc~~officer or director.

On21 ~~October~~Table ~~2, 2017, the Board~~ of Directors appointed Kim Southworth and Dr. Edward E Jacobs, Jr MD as directors and Barry K. Epling resigned as Chairman. FHI donated 9,628.568 shares of the Company’s common stock to the Breath of Life Foundation, a Section 501(c)(3) non-profit organization. At that time, these shares constituted 51.84% of the Company’s issued and outstanding shares and, as part of the grant, Breath of Life granted the Company’s Board of Directors an irrevocable proxy to vote them. With these actions, Barry K. Epling terminated his relationship with the Company as an owner (direct or indirect), officer or director.Contents

41September ~~Table~~2018, ~~of Contents~~

Subsequent to the establishment of the Series A-B-C-D Preferred Stock, the enhanced voting privileges provided to the Series A ~~and Series~~ -B-C-D Preferred ~~Stock~~Stockholders ~~holders~~ will provide them with sufficient voting authority to exercise control over the Company’s corporate functions. ~~For year ending December 2023~~ Currently, the control voting privileges are held ~~by the Board and Dr, Edward Jacobs,~~ with the ~~irrevocable~~Preferred ~~assignment~~Series ofC ~~the~~ voting ~~power~~rights ~~having~~owned ~~been granted to the Board~~ by ~~Breathe~~James ofE. Life Foundation for 9,628,568 of common shares and Essence World Wide (750,000 Preferred A shares), Essence Now Ltd (500,000 Preferred A shares) and LiveStock Impact, Ltd (750,000 Preferred A shares and 1,500,000 Preferred B shares), as well as Dr Jacobs’ BioScience Associates Ltd voting power (850,000 Preferred A shares and 750,000 Preferred B shares)Keener.

Item 13 - Certain Relationships and Related Transactions, and Director Independence

Relationships and Transactions

Independence Transactions with ~~Relate~~Related Persons

~~BioScience~~Azuna ~~Associates~~Health

AsConflicts ~~noted in the accounting, BioScience Associates, Ltd. founded and managed by Dr. Edward E. Jacobs, Jr, Director and Chief Executive Officer~~ of the Company. converted $24,000 debt in 2020 and $3300 interest in 2023 and for converted to 600,000 shares of Series A Preferred Stock after December 31, 2020 and a further 750,000 shares of Preferred B in 2023.Interest

~~Essence~~Certain ~~Worldwide,~~conflicts ~~Ltd.~~of ~~Essence~~interest ~~Now~~could arise in the future, ~~Ltd.~~including, ~~and~~but ~~LiveStock~~not ~~Impact~~limited to, ~~Ltd~~the following:

~~The~~* ~~Essence~~None ~~companies have granted licenses for the Company’s principal nutraceutical products in exchange for 1,250,000 shares~~ of ~~Series~~our Aofficers ~~Preferred~~and ~~Stock.~~directors ~~The~~is ~~Essence~~required ~~companies~~to ~~are~~commit ~~managed~~their byfull ~~Michele~~time ~~Sheriff,~~to ~~who~~our ~~otherwise~~affairs ~~has no involvement in the Company’s activities. LiveStock Impact Ltd granted exclusive licenses for its Equine~~ and ~~Canine formulas in exchange for 750~~,~~000~~ ~~Series A shares and 1~~accordingly,~~500,000~~ ~~Series~~they ~~B shares. LiveStock Impact Ltd is managed by Arthur Porras. The Company anticipates that it~~ may ~~license~~have ~~additional~~conflicts ~~products~~of orinterest ~~technologies from Essence and LiveStock~~ in ~~the~~allocating ~~future,~~management ~~which~~time ~~would~~among ~~increase~~various ~~its~~business ~~voting privileges and rights to additional common shares~~activities.

~~Conflicts~~* In the course of ~~Interest~~their other business activities, our officers and directors may become aware of investment and business opportunities that may be appropriate for presentation to us as well as the other entities with which they are affiliated. They may have conflicts of interest in determining to which entity a particular business opportunity should be presented.

~~Certain~~* ~~conflicts~~Our ofofficers ~~interest~~and ~~could~~directors ~~arise~~may in the future become affiliated with entities, including other blank check companies, ~~but~~engaged ~~not~~in ~~limited~~business activities similar to, ~~the~~those ~~following:~~intended to be conducted by us.

* None of our officers and directors is required to commit their full time to our affairs and, accordingly, they may have conflicts of interest in allocating management time among various business activities. * In the course of their other business activities, our officers and directors may become aware of investment and business opportunities that may be appropriate for presentation to us as well as the other entities with which they are affiliated. They may have conflicts of interest in determining to which entity a particular business opportunity should be presented. * Our officers and directors may in the future become affiliated with entities, including other blank check companies, engaged in business activities similar to those intended to be conducted by us. * Since all of our directors own shares of our common stock that could be sold, in whole or in part, as a negotiated element of a business acquisition, our board may have a conflict of interest in determining whether a particular target business is appropriate to effect a business combination. The personal and financial interests of our directors and officers may influence their motivation in identifying and selecting a target business and completing a business combination.

In general, officers and directors of a Delaware corporation are required to present business opportunities to a corporation if:

* the corporation could financially undertake the opportunity. * the opportunity is within the corporation’s line of business; and * it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

~~Accordingly,~~* ~~as a result of multiple business affiliations, our officers and directors may have similar legal obligations relating to presenting business opportunities meeting~~ the ~~above-listed criteria to multiple entities. In addition, conflicts of interest may arise when our board evaluates a particular business~~ opportunity ~~with~~is ~~respect~~within to the ~~above-listed~~corporation’s ~~criteria.~~line ~~We cannot assure you that any~~ of ~~the~~business; ~~above-mentioned conflicts will be resolved in our favor.~~ and

~~Director~~* ~~Independence~~it would not be fair to the corporation and its stockholders for the opportunity not to be brought to the attention of the corporation.

~~The~~Accordingly, ~~Board~~as ofa ~~Directors~~result ~~has~~of ~~determined~~multiple ~~that~~business ~~none~~affiliations, ofour ~~its~~officers and directors ismay ~~“independent”~~have ~~under~~similar ~~the~~legal ~~criteria~~obligations ~~set~~relating ~~forth~~to inpresenting ~~Rule~~business ~~5065(a)(2)~~opportunities ofmeeting the ~~Nasdaq~~above-listed ~~Listing~~criteria ~~Rules. The~~to ~~Board~~multiple ~~does~~entities. ~~not~~In ~~have a separately designated audit~~addition, ~~nominating,~~conflicts orof ~~compensation~~interest ~~committee,~~may soarise ~~the~~when ~~functions~~our ~~normally~~board ~~attributed~~evaluates toa ~~these~~particular ~~committees~~business ~~are~~opportunity ~~performed~~with byrespect to the ~~entire~~above-listed ~~board~~criteria. ~~Accordingly,~~We ~~none~~cannot ofassure ~~our~~you ~~directors is “independent” under applicable Nasdaq Listing Rules~~ that ~~define~~any ~~independence~~of ~~for~~the ~~purposes~~above-mentioned ofconflicts ~~directors~~will ~~performing~~be ~~the~~resolved ~~functions~~in ofour ~~such committees~~favor.

~~Item~~Director ~~14 - Principal Accountant Fees and Services~~Independence

~~Below~~The isBoard ~~the~~of ~~table~~Directors has determined that none of ~~Audit~~its ~~Fees~~directors ~~(amounts~~is “independent” under the criteria set forth in ~~US$~~Rule 5065(a)(2) ~~billed~~of the Nasdaq Listing Rules. The Board does not have a separately designated audit, nominating, or compensation committee, so the functions normally attributed to these committees are performed by the entire board. Accordingly, none of our ~~auditors~~directors inis ~~connection~~“independent” ~~with~~under ~~the~~applicable ~~audit~~Nasdaq Listing Rules that define independence for purposes of directors performing the ~~Company’s~~functions ~~annual~~of ~~financial~~such ~~statements:~~committees.

	Audit Services		Audit Related Fees	Tax Fees		Other Fees
Year Ended December 31, 2023	$	16,500	$	$	0	$	0
Year Ended December 31,2022	$	12,960	$	$	0	$	0

Table of Contents

42Item ~~Table~~14 of- ~~Contents~~Principal Accountant Fees and Services

~~Item~~Below 15is -the ~~Exhibits~~table ~~and~~of ~~Financial~~Audit ~~Statement~~Fees ~~Schedules~~(amounts in US$) billed by our auditors in connection with the audit of the Company’s annual financial statements:

31.1	Section 302 Certifications under Sarbanes-Oxley Act of 2002
		Audit Services		Audit Related Fees		Tax Fees		Other Fees
32.1	Section 906 Certification under Sarbanes Oxley Act of 2002
Year Ended December 31, 2024		$	53,575.00	$	20,858.00	$	0	$	0
Year Ended December 31, 2023		$	33,000.00	$	20,456.5	$	0	$	0

Item 1615 - ~~Form~~Exhibits ~~10-K~~and ~~Summary~~Financial Statement Schedules

None

3.1	Articles of Incorporation (with amendments)

10.1	James E Keener Employment Agreement

10.2	Director’s Agreement

31.1	Section 302 Certifications under Sarbanes-Oxley Act of 2002

32.1	Section 906 Certification under Sarbanes Oxley Act of 2002

43Item ~~Table~~16 of- ~~Contents~~Form 10-K Summary

Pursuant to the requirements of Section 13 or 15(d) of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on April 10, 2024.None

~~BioAdaptives,~~23 ~~Inc.~~Table of Contents

~~/s/~~Pursuant ~~Edward~~to E.the ~~Jacobs~~requirements of Section 13 or 15(d) of the Exchange Act of 1934, Jrthe registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized on March 24, 2023.

~~Edward~~BioAdaptives, Inc. /s/ James E. ~~Jacobs,~~Keener JrJames E. Keener Chief Executive Officer(Principal Executive Officer)

~~Chief~~Pursuant ~~Executive~~to ~~Officer~~the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

BioAdaptives, Inc. /s/James E. Keener Chief Financial Officer(Principal ~~Executive~~Financial Officer) April 15, 2025

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.24

BioAdaptives, Inc.

/s/ Robert E. Ellis

Robert E. Ellis

President and Chief Financial Officer

(Principal Financial Officer)

April 10, 2024

Filing Compare · BIOADAPTIVES, INC.